Doctoral Thesis

Development of new nucleoside analogues as PET imaging agents for monitoring gene expression

Author(s):
Martić, Miljen

Publication Date:
2008

Permanent Link:
https://doi.org/10.3929/ethz-a-005666885

Rights / License:
In Copyright - Non-Commercial Use Permitted
DEVELOPMENT OF NEW NUCLEOSIDE ANALOGUES AS PET IMAGING AGENTS FOR MONITORING GENE EXPRESSION

A dissertation submitted to

ETH ZURICH

for the degree of

Doctor of Sciences

presented by

MILJEN MARTIĆ
Dipl. Ing. Kemije, University of Zagreb, Croatia

born on January 14th, 1979

citizen of Zagreb, Croatia

accepted on the recommendation of

Prof. Dr. P.A. Schubiger, examiner
Prof. Dr. L. Scapozza, co-examiner
Prof Dr. S.M. Ametamey, co-examiner

2008
Acknowledgements

First of all, I would like to thank Prof. August Schubiger and Prof. Simon Ametamey for their support and understanding during entire duration of the thesis. I certainly hope they didn’t regret waiting for me two years to start the Ph.D.

… Prof. Leonardo Scapozza, Dr. Remo Perozzo, Anja Stoeffel and Yvonne Westermeier from the University of Geneva for their support regarding enzyme kinetics and for docking countless numbers of molecules.

… Dr. Anass Johayem for introducing me into the field and help at the beginning of the synthesis.

… Dr. Jean-Fred Salazar and Sabine Baumann for teaching me basics of cell culture and ex-vivo studies. Thank you for your patience.

… Dr. Michael Honer and Claudia Keller for help during animal experiments, even when the wrong solvent was used ;-)  

… Sandha Keller who helped me so many times with those “easy” administrative issues.

… Aileen Höhne, a “personal secretary”, without whom I would be lost in schedule. Thank you for the friendship and those 3 nice years in the lab ☺

… Dr. Jessica Becaud for the nice friendship and support with so many scientific and technical issues ☺

… my dear “Boss”, Dr. Tobias Ross, a good friend with a lot of ideas and positive energy! ☺

… Dr. Linjing Mu for many fruitful scientific and deep spiritual discussions in the train.

… Keith Graham for the friendship and giving me different, industrial, point of view on the science and everything around it ☺

… Mathias Nobst for the help on all those technical issues in which I am completely lost!

… Lab-mates Miray Demirer, Phoebe Lam, Marianne Kehl and Cindy Baumann, for the friendship and making those long hours in the lab very interesting ☺

… Dr. Christophe Lucatelli, Dr. Thomas Mindt and Dr. Meri De Angelis for many good ideas how to overcome chemistry problems.

… Dominic Franck, Simon Schwarz, Eva Geissler, Dr. Samson Fabrice, Dr. Thomas Ebenhan, Dr. Thomas Nauser, Dr. Volkmar Uhlendorf and everybody else for the nice atmosphere in the lab.

… Tanasis Galiciadis and Tibor Kovacs, for excellent professional IT support and advices.
… Sanja for the unlimited support, even when “why the hell not” is not an easy option! But the only right one ;-) 

… a very special thanx goes to mysterious CS for making my life interesting ;-) 

At the end I would like to express a big THANK YOU to my parents who kept me going and kept believing in me my whole life! Hvala vam! ☺
Table of Contents

List of abbreviations 7

Summary 11

Zusammenfassung 13

1 Introduction 17
   1.1 Positron Emission Tomography 18
   1.2 Thymidine Kinase (TK) 23
   1.3 In vivo Imaging of Gene Expression 29
   1.4 Molecular Modeling 33
   1.5 References 36

Aim and Scope of This Study 41

2 Synthetic Approaches Toward FHBT 43
   2.1 Introduction 44
   2.2 Novel Synthetic Strategies to FHBT 47
   2.3 Fluorine-18 radiolabeling of [18F]FHBT 58
   2.4 Conclusion and Outlook 61
   2.5 Materials and Methods 63
   2.6 References 70

3 Development of a novel C-6 substituted pyrimidine derivative for gene therapy monitoring 77
   1 Introduction 78
   2 Results and Discussion 79
   3 Conclusions 87
   4 Materials and Methods 87
   5 References 96

4 Overall Conclusions & Outlook 99

Curriculum Vitae 103
List of Abbreviations

$[^{18}\text{F}]\text{FHBG}$: $9-[^{18}\text{F}]\text{fluoro-3-(hydroxymethyl)butyl} \text{guanine}$

$[^{18}\text{F}]\text{FLT}$: $[^{18}\text{F}]\text{fluoro-3'-deoxy-3'-L-fluorothymidine}$

$[^{18}\text{F}]\text{Fluoromethyl HHT}$: $6-(2\text{-hydroxy-hydroxypropyl})-5-[^{18}\text{F}]\text{fluoromethyl (1H,3H)-pyrimidine-2,4-dione}$

$[^{18}\text{F}]\text{N-Me DHBT}$: $6-(3-[^{18}\text{F}]\text{fluoro-2-(hydroxymethyl)propyl})-1,5$-$\text{dimethylpyrimidine-2,4(1H,3H)-dione}$

3D: three dimensional

Ac: acetyl

AcOH: acetic acid

ACV: acyclovir, 9-(2-hydroxymethyl)guanine

ADP: adenosine 5'-diphosphate

AIBN: 2,2'-azobis(isobutyronitrile)

ATP: adenosine 5'-triphosphate

AZT: azidothymidine

BLI: bioluminescence imaging

Boc: $\text{tert}$-butoxycarbonyl

br: broad

BrUdR: bromodeoxyuridine

Cbz: benzyloxycarbonyl

CCD: charge coupled device

d: doublet

DAD: diode array detector

DAST: diethylaminosulfur trifluoride

dC: deoxycitidine

DHBT: 6-(3-hydroxy-2-(hydroxymethyl)propyl)-5-methylpyrimidine-2,4(1H,3H)-dione

DMAP: 4-dimethylaminopyridine

DMF: dimethylformamide

DMSO: dimethylsulfoxide

DNA: deoxyribonucleic acid
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>dT</td>
<td>deoxythymidine, 2’-deoxythymidine</td>
</tr>
<tr>
<td>dTDP</td>
<td>deoxythymidine 5’-diphosphate</td>
</tr>
<tr>
<td>dTMP</td>
<td>deoxythymidine 5’-monophosphates</td>
</tr>
<tr>
<td>dTTP</td>
<td>deoxythymidine 5’-triphosphate</td>
</tr>
<tr>
<td>dU</td>
<td>2’-deoxyuridine</td>
</tr>
<tr>
<td>dUDP</td>
<td>deoxyuridine 5’-diphosphate</td>
</tr>
<tr>
<td>dUMP</td>
<td>deoxyuridine 5’-monophosphate</td>
</tr>
<tr>
<td>dUTP</td>
<td>deoxyuridine 5’-triphosphate</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylenediamine tetraacetic acid</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme linked immunosorbent assay</td>
</tr>
<tr>
<td>FGCV</td>
<td>8-fluoroganciclovir</td>
</tr>
<tr>
<td>FHBT</td>
<td>6-(3-fluoro-2-(hydroxymethyl)propyl)-5-methyl-pyrimidine-2,4(1H,3H)-dione</td>
</tr>
<tr>
<td>FHPG</td>
<td>9-[3-fluoro-1-hydroxy-2-propoxymethyl]guanine</td>
</tr>
<tr>
<td>FIAU</td>
<td>2′-fluoro-2′-deoxy-1-β-D-arabinofuranosyl-5-iodouracil</td>
</tr>
<tr>
<td>FIRU</td>
<td>1-(2′-fluoro-2′-deoxy--D-ribofuranosyl)-5-iodouracil</td>
</tr>
<tr>
<td>FLI</td>
<td>fluorescent imaging</td>
</tr>
<tr>
<td>FMAU</td>
<td>1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)thymine</td>
</tr>
<tr>
<td>FPCV</td>
<td>8-fluoropenciclovir</td>
</tr>
<tr>
<td>GCV</td>
<td>ganciclovir, 9-(1,3-dihydroxy-2-propoxy-methyl)-guanine</td>
</tr>
<tr>
<td>GFP</td>
<td>green fluorescent protein</td>
</tr>
<tr>
<td>GOLD</td>
<td>genetic optimisation for ligand docking</td>
</tr>
<tr>
<td>HPLC</td>
<td>high performance liquid chromatography</td>
</tr>
<tr>
<td>HSV1</td>
<td>herpes simplex virus type 1</td>
</tr>
<tr>
<td>hTK</td>
<td>human thymidine kinase</td>
</tr>
<tr>
<td>hTK1</td>
<td>human thymidine kinase 1</td>
</tr>
<tr>
<td>hTK2</td>
<td>human thymidine kinase 2</td>
</tr>
<tr>
<td>IUdR</td>
<td>5-iodo-2'-deoxyuridine</td>
</tr>
<tr>
<td>IVFRU</td>
<td>(E)-5-(2-iodovinyl)-2′-fluoro-2′-deoxyuridine</td>
</tr>
<tr>
<td>$K_{\text{cat}}$</td>
<td>turnover number</td>
</tr>
<tr>
<td>$K_i$</td>
<td>inhibition constant</td>
</tr>
<tr>
<td>$K_m$</td>
<td>Michaelis-Menten constant</td>
</tr>
<tr>
<td>LB-Medium</td>
<td>Luria-Bertani medium</td>
</tr>
<tr>
<td>LDA</td>
<td>lithium diisopropylamide</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>LDH</td>
<td>lactate dehydrogenase</td>
</tr>
<tr>
<td>LOR</td>
<td>line of response</td>
</tr>
<tr>
<td>m</td>
<td>multiplet</td>
</tr>
<tr>
<td>MeOH</td>
<td>methanol</td>
</tr>
<tr>
<td>MS</td>
<td>mass spectroscopy</td>
</tr>
<tr>
<td>MTr</td>
<td>4-methoxytrityl</td>
</tr>
<tr>
<td>MW</td>
<td>microwave</td>
</tr>
<tr>
<td>n</td>
<td>neutron</td>
</tr>
<tr>
<td>n.c.a.</td>
<td>non carrier added</td>
</tr>
<tr>
<td>NADH</td>
<td>nicotinamide-adenine dinucleotide, reduced form</td>
</tr>
<tr>
<td>N-Me DHBT</td>
<td>6-(3-hydroxy-2-(hydroxymethyl)propyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione</td>
</tr>
<tr>
<td>NMR</td>
<td>nuclear magnetic resonance</td>
</tr>
<tr>
<td>OD</td>
<td>optical density</td>
</tr>
<tr>
<td>p</td>
<td>proton</td>
</tr>
<tr>
<td>para</td>
<td>para</td>
</tr>
<tr>
<td>PAGE</td>
<td>polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>PCV</td>
<td>penciclovir, 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3H-purin-6-one</td>
</tr>
<tr>
<td>PDB</td>
<td>protein data bank</td>
</tr>
<tr>
<td>PEP</td>
<td>phosphoenolpyruvate</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PK</td>
<td>pyruvate kinase</td>
</tr>
<tr>
<td>PMB</td>
<td>p-methoxybenzyl</td>
</tr>
<tr>
<td>PMSF</td>
<td>phenyl methyl sulfonyl fluoride</td>
</tr>
<tr>
<td>POCl3</td>
<td>phosphorous oxychloride</td>
</tr>
<tr>
<td>PSF</td>
<td>penicillin streptomycin fungizone</td>
</tr>
<tr>
<td>q</td>
<td>quartet</td>
</tr>
<tr>
<td>RCY</td>
<td>radiochemical yield</td>
</tr>
<tr>
<td>RMSD</td>
<td>root mean square deviation</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>ROI</td>
<td>region of interest</td>
</tr>
<tr>
<td>RPMI</td>
<td>Roswell Park Memorial Institute</td>
</tr>
<tr>
<td>s</td>
<td>singlet</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>SDS</td>
<td>sodium dodecyl sulfate</td>
</tr>
<tr>
<td>S$_{N}2$</td>
<td>bimolecular nucleophilic substitution</td>
</tr>
<tr>
<td>SPECT</td>
<td>single-photon emission computed tomography</td>
</tr>
<tr>
<td>t</td>
<td>triplet</td>
</tr>
<tr>
<td>TBAF</td>
<td>tertabutylammonium fluoride</td>
</tr>
<tr>
<td>Tf</td>
<td>triflate, trifluoromethanesulfonyl</td>
</tr>
<tr>
<td>THF</td>
<td>tetrahydrofurane</td>
</tr>
<tr>
<td>TK</td>
<td>thymidine kinase enzyme</td>
</tr>
<tr>
<td>tk</td>
<td>thymidine kinase gene</td>
</tr>
<tr>
<td>TK1</td>
<td>human cytosolic thymidine kinase</td>
</tr>
<tr>
<td>TK2</td>
<td>human mitochondrial thymidine kinase</td>
</tr>
<tr>
<td>TLC</td>
<td>thin layer chromatography</td>
</tr>
<tr>
<td>Tris</td>
<td>tris(hydroxymethyl)aminomethane</td>
</tr>
<tr>
<td>Ts</td>
<td>tosyl, $p$-toluensulfonyl</td>
</tr>
<tr>
<td>UV</td>
<td>ultra violet</td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>rate of enzyme catalyzed reaction at infinite concentration of substrate</td>
</tr>
<tr>
<td>XTT</td>
<td>2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazoli um-5-carboxanilide</td>
</tr>
</tbody>
</table>
Summary

Gene therapy offers a promising new treatment modality for a variety of inherited and acquired disorders. All of the gene therapy approaches are based on the common strategy to use gene delivery to effect production of a therapeutic protein in a target tissue. For application in humans as well as for research purposes, it is critically important to have a noninvasive imaging modality such as positron emission tomography (PET), which offers the possibility of monitoring the location, magnitude, and duration over time of the expression of delivered therapeutic genes. One of the most promising approaches in imaging gene expression uses the gene of the viral enzyme herpes simplex virus thymidine kinase (HSV1 tk) as a reporter gene in combination with an appropriate reporter probe. Several pyrimidine and purine analogues labeled with F-18 or I-124 have been synthesized and evaluated as potential imaging agents for the HSV1 TK expression in vivo. These two classes of substrates are selectively phosphorylated by HSV1 TK to their monophosphates and thereby metabolically trapped in transfected cells.

Our investigations were prompted by the need to develop PET imaging agents that lack the disadvantages of already existing reporter probes such as cytotoxicity, unfavorable pharmacokinetics, and by-stander effect. The major advantage of pyrimidine analogues over the purine ones is that pyrimidine analogues do not show any or a very low by-stander effect.

The first chapter of this thesis gives a brief introduction on PET, HSV1 TK and its substrate acceptance properties, comparison of HSV1 TK to human TK, and basic approaches to gene therapy monitoring. Finally, a short introduction on molecular modeling, especially docking procedure concludes the first chapter.

Chapter 2 describes the synthetic attempts made to prepare FHBT, a fluoro analogue of the lead compound, 6-(1,3-dihydroxy-isobutyl)thymine (DHBT). Several synthetic strategies that were designed to prepare FHBT starting from DHBT or its two intermediates were not successful. In most cases, the anticipated reaction products were not formed, either because the intermediates or the starting material decomposed, or underwent intramolecular cyclization. The use of different protecting groups such as PMB, Cbz and Boc did not lead to the expected results. In one case, by protecting a hydroxyl group in DHBT with MTr and reacting with DAST, traces of the target compound, FHBT, were detected. An attempt was
made to prepare the $[^{18}\text{F}]$FHBT starting from a tosyl precursor. Although the F-18 labeled MTr-protected intermediate was synthesized, no traces of $[^{18}\text{F}]$FHBT could be found after the deprotection step since the radiolabeled intermediate decomposed or underwent intramolecular cyclization.

In Chapter 3 the focus is on the preparation of a novel C-6 substituted radiolabeled HSV1 TK substrate. In order to prevent intramolecular cyclization and undesired side reactions described in Chapter 2, a methyl group at the N-1 position of the pyrimidine ring was introduced. Molecular modeling studies were employed to explore the outcome of the substitution in the N-1 position. It was found that the introduction of a methyl group in the N-1 position of the pyrimidine ring should not have any detrimental effects on the binding properties of the methylated non-fluorinated ligand, N-Me DHBT.

The total synthesis of the novel non-fluorinated key intermediate, N-Me DHBT, was accomplished in a 10-step reaction sequence in 13% overall yield. Enzymatic tests confirmed that N-Me DHBT is indeed a substrate for HSV1 TK. Additionally, cytotoxicity experiments on B16F1 cell lines showed that N-Me DHBT is not cytotoxic up to a concentration of 1 mM. Encouraged by these promising in vitro results, the fluoro analogue, N-Me FHBT was prepared. The introduction of a methyl group in the N-1 position of pyrimidine ring effectively prevented intramolecular cyclization and undesired side reactions, making the synthesis of the “cold” reference N-Me FHBT possible.

A suitable precursor for the radiosynthesis of $[^{18}\text{F}]$N-Me FHBT was prepared in 30% yield. The radiolabeling was carried out under classical conditions with potassium $[^{18}\text{F}]$fluoride and kryptofix 2.2.2 in acetonitrile at 90°C and the fluorinated intermediate was produced in 35% conversion. The cleavage of the MTr protecting group was accomplished by using 5% HCl in methanol. Radiochemically pure $[^{18}\text{F}]$N-Me FHBT (>99%) was obtained in 25% RCY (decay corrected) after the HPLC purification.

Further in vitro validation (cell uptake studies) as well as in vivo studies are necessary to fully assess the applicability of $[^{18}\text{F}]$N-Me FHBT for the monitoring of HSV1 TK expression in vivo. Although only N-Me DHBT was validated in vitro, the literature suggests that the binding affinities of N-Me DHBT and N-Me FHBT should be in the same range. Therefore, it can be concluded that $[^{18}\text{F}]$N-Me FHBT is a promising candidate for monitoring HSV1 TK expression in vivo.
Zusammenfassung


Das erste Kapitel dieser Arbeit enthält eine kurze Einführung in PET, HSV1 TK und seine Substratspezifität, einen Vergleich von HSV TK1 mit der humanen TK, und grundlegende Ansätze der Gentherapieüberwachung. Eine kurze Einführung ins Molecular Modeling mit Schwerpunkt auf die Docking-Methode beschliesst das erste Kapitel.

Kapitel 2 beschreibt die synthetischen Ansätze zur Herstellung von FHBT, des Fluor-Analogs der Leitstruktur 6-(1,3-Dihydroxy-isobutyl)thymin (DHBT). Keine der etlichen synthetischen Strategien, die zur Darstellung von FHBT aus dem Ausgangsstoff DHBT oder einer seiner zwei Vorstufen führen sollten, war erfolgreich. Im Allgemeinen wurden die erwarteten Reaktionsprodukte nicht gebildet, entweder aufgrund Zersetzung der Zwischenstufen oder des Ausgangsmaterials, oder ihrer intramolekularen Zykлизierung. Die Verwendung verschiedener
Schutzgruppen wie zum Beispiel PMB, Cbz oder Boc führte nicht zu den erwarteten Resultaten. In einem Fall, in welchem MTr-geschütztes DHBT mit DAST umgesetzt wurde, war es möglich, Spuren der Zielstruktur FHBT zu detektieren. Es wurde der Versuch unternommen, \(^{18}\text{F}\)FHBT ausgehend vom Tosyl-Vorläufer herzustellen. Obwohl die F-18 markierte, MTr-geschützte Zwischenstufe synthetisiert werden konnte, war es nicht möglich, nach dem Entschützungsschritt \(^{18}\text{F}\)FHBT nachzuweisen, da währenddessen die Zersetzung oder intramolekulare Zyklisierung der radiomarkierten Zwischenstufen auftrat.


1 Introduction
1.1 Positron Emission Tomography (PET)

Positron Emission Tomography (PET) is a nuclear medicine, quantitative imaging modality that produces a three-dimensional (3D) image or a map of functional processes in the body. Image map is reconstructed based on the coincidence detection of two gamma ray photons produced in annihilation process. In the process of annihilation, a positron (ejected from positron emitting radionuclide) and an electron from the surrounding medium are annihilated and two gamma ray photons are formed.

1.1.1 Positron Decay and Positron Emitting Radionuclides

The positron is the antiparticle or the antimatter counterpart of the electron. The positron has an electric charge of +1, a spin of 1/2, and the same mass as an electron. Nuclei that are “proton rich” (i.e., have an N/Z ratio less than that of the stable nuclei) can decay by $\beta^+$-particle emission accompanied by the emission of a neutrino. After $\beta^+$ particle emission, the daughter nuclide has an atomic number 1 less than the parent nuclide (Figure 1.1).

Beta plus decay can only happen inside nuclei when the absolute value of the binding energy of the daughter nucleus is higher than that of the mother nucleus. The difference between these energies goes into the reaction of converting a proton ($p^+$) into a neutron ($n^0$), a positron ($e^+$) and a neutrino ($\nu_e$) and into the kinetic energy of these particles.

$$p^+ \rightarrow n^0 + e^+ + \nu_e$$

In the annihilation process energy and momentum are conserved. Therefore, the result is emission of 2 gamma rays, each having an energy equal to the rest-mass energy of electron or positron ($mc^2 = 511$ keV), which propagate in the opposite direction of each other. In the Table 1.1 are listed positron emitting radionuclides commonly used in research.
Figure 1.1. Graphical interpretation of beta plus decay [1]

Table 1.1. Most commonly used positron emitting radionuclides [2]

<table>
<thead>
<tr>
<th>Radionuclide</th>
<th>Half-life</th>
<th>$\beta^+$ fraction (%)</th>
<th>Max Energy (MeV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{11}$C</td>
<td>20.4 min</td>
<td>99</td>
<td>0.96</td>
</tr>
<tr>
<td>$^{13}$N</td>
<td>9.96 min</td>
<td>100</td>
<td>1.20</td>
</tr>
<tr>
<td>$^{15}$O</td>
<td>123 sec</td>
<td>100</td>
<td>1.74</td>
</tr>
<tr>
<td>$^{18}$F</td>
<td>109.8 min</td>
<td>97</td>
<td>0.63</td>
</tr>
<tr>
<td>$^{38}$K</td>
<td>7.6 min</td>
<td>100</td>
<td>2.68</td>
</tr>
<tr>
<td>$^{62}$Cu</td>
<td>9.74 min</td>
<td>98</td>
<td>2.93</td>
</tr>
<tr>
<td>$^{64}$Cu</td>
<td>12.7 hrs</td>
<td>19</td>
<td>0.65</td>
</tr>
<tr>
<td>$^{68}$Ga</td>
<td>68.3 min</td>
<td>90</td>
<td>1.83</td>
</tr>
<tr>
<td>$^{72}$As</td>
<td>26 hrs</td>
<td>88</td>
<td>2.52</td>
</tr>
<tr>
<td>$^{73}$Se</td>
<td>7.1 hrs</td>
<td>65</td>
<td>1.32</td>
</tr>
<tr>
<td>$^{75}$Br</td>
<td>98 min</td>
<td>75.5</td>
<td>1.74</td>
</tr>
<tr>
<td>$^{76}$Br</td>
<td>16.1 hrs</td>
<td>100</td>
<td>1.90</td>
</tr>
<tr>
<td>$^{82}$Rb</td>
<td>78 sec</td>
<td>96</td>
<td>3.15</td>
</tr>
<tr>
<td>$^{86}$Y</td>
<td>14.7 hrs</td>
<td>34</td>
<td>1.30</td>
</tr>
<tr>
<td>$^{120}$I</td>
<td>1.35 hrs</td>
<td>64</td>
<td>4.10</td>
</tr>
<tr>
<td>$^{124}$I</td>
<td>4.18 days</td>
<td>0.22</td>
<td>1.50</td>
</tr>
</tbody>
</table>
1.1.2 Data Acquisition and Image Reconstruction

Reconstruction of the three-dimensional image is based on the coincidence detection of two 511 keV gamma ray photons emitted after the annihilation of positron, from the positron emitter, and an electron, form the surrounding medium. Since formed photons travel in 180° to each other, only the coincidence of simultaneous photon detection on the opposite sides of the detector is recorded and stored for later processing. The virtual line connecting those two detection sites is called the line of response (LOR). The more lines of response, the higher resolution can be obtained. The position of the radioisotope within the investigated subject can be computed based on the intersections of LORs (Figure 1.2). Therefore, it is crucial to inject enough radioactive tracer to obtain sufficient resolution of the PET images.

![Diagram](image1.png)

**Figure 1.2.** Animal experimental setup for the tracer evaluation with PET [3]. The radiolabeled compound is injected into an animal, after which the animal is anaesthetized and placed inside the PET scanner. Emitted gamma rays are detected and the image is reconstructed by intersecting lines of response.
1.1.3 Commonly Used Radionuclides for Radiolabeling of Organic Compounds for PET

Most commonly used PET radionuclides are $^{11}$C and $^{18}$F (Figure 1.3). The choice of these two radionuclides lies in their properties: short half-life, easy incorporation into organic molecules and the convenient on-site cyclotron production. In the case of carbon-11, stable $^{12}$C can be replaced with $\beta^+$ emitter $^{11}$C without changing the properties of the compound since all chemical properties remain intact. The disadvantage of C-11 is the short half-life of 20.4 minutes which requires short radiosynthesis time and fast purification procedures [4].

In the case of $^{18}$F, chemical properties of the molecule are changed (unless $^{19}$F is substituted with $^{18}$F). The van der Waals’ radius of the fluorine (1.35 Å) is similar to that of hydrogen (1.20 Å), which means that the size of the molecule would not be affected. However, differences in the electronic character are very pronounced. The half-life of 109.8 minutes allows multi-step radiosynthesis as well as extended PET studies of slower biochemical processes [4]. In addition, the radionuclide has low $\beta^-$ energy of 635 keV, essential for high resolution down to 1 mm in PET images [4].

1.1.4 $^{18}$F Labeling Strategies

The F-18 can be incorporated into organic molecule either by electrophilic or via nucleophilic substitution [5]. Produced radiotracers can be obtained with very high specific radioactivities (50-500 GBq μmol$^{-1}$). However, the maximum theoretical value of $6.3 \times 10^4$ GBq μmol$^{-1}$ is never reached due to contamination with the stable
isotope originating from the radionuclide production, the solvents, chemicals and other sources [5].

**Electrophilic Radiofluorination**

The simplest fluorinating reagent is $[^{18}\text{F}]\text{F}_2$ which provides a facile mean of introducing $^{18}\text{F}$ into electron-rich compounds. However, electrophilic fluorination of aromatic compounds using $\text{F}_2$ is a non-selective method since the oxidizing strength of fluorine may lead to exothermic radical chain reactions with the formation of side products and tars. Methods of $[^{18}\text{F}]\text{F}_2$ production require carrier fluoride (0.1% in neon) [6-9]. As a consequence, $[^{18}\text{F}]\text{F}_2$ cannot be used for the synthesis of radiopharmaceuticals with high specific activity.

**Nucleophilic Radiofluorination**

Nucleophilic substitution reactions with $[^{18}\text{F}]\text{fluoride}$ have been largely developed both for aromatic and aliphatic systems [10]. Usually, they do not require a carrier and thus enable the synthesis of products with high specific activities. The nucleophilic substitution can be performed either directly on a suitable precursor of the target molecule or indirectly via a small labeled precursor [11].

$[^{18}\text{F}]\text{Fluoride}$ anion in its highly solvated form is a poor nucleophile, but a strong base. The need for a reactive naked fluoride requires its combination to large cations, such as tetrabutylammonium, cesium, rubidium, or the presence of the crown ester or aminopolyether with potassium [12-16].

In nucleophilic aliphatic substitution, a leaving group is substitute with $^{18}\text{F}$ in a $\text{S}_\text{N}2$-type reaction [17]. Commonly used leaving groups are mesylate, tosylate, nosylate, triflate, iodide or bromide. The choice of a leaving group is strongly dependent on the substrate which is labeled and the optimization of radiochemical yield (RCY) requires testing of several different leaving groups.
1.2 Thymidine Kinase (TK)

1.2.1 Human Thymidine Kinase (hTK)

Thymidine kinase (EC 2.7.1.75) can be found in most living cells. In mammalian cells, it is present in two forms, hTK1 and hTK2. They are coded by different genes, have different substrate specificity and different substrate kinetics, differ in phosphate donor specificity and are located in different cellular compartments. TKs have a key function in the synthesis of DNA and thereby in the cell proliferation, thus making it an excellent potential target for measuring the cell proliferation.

Thymidine kinase 1 (hTK1), also known as “soluble” or human cytosolic thymidine kinase, is the most studied among the salvage pathway enzymes. hTK1, is widely distributed in human tissues, but being S-phase correlated, it is only detected in proliferating cells, either normally growing or malignant. It is characterized by a high substrate specificity, accepting only close analogues of thymidine. Especially important thymidine analogue is PET tracer [\(^{18}\text{F}\)]FLT, which is used to image cell proliferation [18].

After the crystallization of hTK in 2005 [19], structure and binding mode have been revealed (Figure 1.4). Unexpectedly, thymidine as a natural substrate is tied by a hydrogen bond network to a protein backbone. Amino acids which form interactions with thymidine are: Met28, Phe101, Leu124, Phe128, Phe133, Thr163, Val172, Val174, Tyr181. This binding mode of thymidine is in contrast with most of the other nucleoside/nucleotide kinases, which bind it via side chains. The adaptation of the active site to substrate is clearly not possible since substrate is bound via backbone. However, X-ray structure revealed that N-3 position of thymidine points out of the active site, making it the most promising site for analogue preparation.

![Figure 1.4. X-ray structure of hTK (PDB ID: 1W4R)](image)
Thymidine kinase 2 (hTK2), or mitochondrial thymidine kinase is present in most tissues. The amount of enzyme is in the correlation to the number of mitochondria and is independent of the growth state of the cell [20]. When compared to the level of TK1 in proliferating cells, the level of TK2 is low, but TK2 becomes significant in resting and terminally differentiated cells, such as muscle or brain and unstimulated lymphocytes, where TK1 activity is barely detectable [21, 22]. In tissues, where de novo synthesis of DNA precursors is undetectable, TK 2 is likely to be responsible for the supply of deoxynucleotides required for the mitochondrial DNA synthesis due to the low penetration of thymidine monophosphate (dTMP) through the mitochondrial membrane [23]. Unlike hTK1, hTK2 phosphorylates wider range of pyrimidine analogues as well as deoxycytidine (dC), deoxyuridine (dU), azidothymidine (AZT) and fluroarabino-furalosyl-iodouracil (FIAU) [24].

1.2.2 Salvage Pathway

Salvage pathways are used to recover bases and nucleosides that are formed during degradation of RNA and DNA. Thymidine kinase is one of the salvage pathway enzymes. In the presence of adenosine triphosphate (ATP) and Mg$^{2+}$, it catalyzes the phosphorylation of the thymidine (dT) into thymidine monophosphate (dTMP). The $\gamma$-phosphate group of the ATP is transferred to the 5`-OH group of thymidine thus producing dTMP. Thymidine monophosphate is subsequently further phosphorylated to the corresponding diphosphate (dTDP) and finally to triphosphate (dTTP) which is used as a DNA building block (Scheme 1.1). In addition to the salvage pathway, cells can synthesize phosphorylated nucleotides via de novo synthetic pathway. In the de novo pathway, thymidine monophosphate is produced by the methylation of deoxyuridine monophosphate (dUMP) in the reaction catalyzed by thymidylate synthetase in the presence of methylene tetrahydrofolate (Scheme 1.1).
Scheme 1.1. Graphical representation of “salvage pathway” and “de novo synthesis”
1.2.3 Herpes Simplex Virus Type 1 Thymidine Kinase (HSV1 TK)

HSV1 TK (EC 2.7.1.21) is a multifunctional cellular enzyme characterized by the wide substrate acceptance (Figure 1.5). The size and the shape of its active site make it possible to accommodate and phosphorylate large number of pyrimidine as well as purine analogues. Based on the X-ray analysis of the compounds co-crystallized with HSV1 TK, single-point mutations and molecular modeling studies, it is known that following amino acids influence the binding properties and the catalytic activity of viral TK: His58, Glu83*, Trp88, Ile100*, Tyr101*, Met121, Gln125*, Met128, Tyr132, Arg163*, Tyr172, Arg220, Arg222, Glu225*. While amino acids marked with (*) form H-bond interactions with the natural substrate thymidine, the remaining amino acids form H-bond interactions with other known substrates, such as penciclovir (PCV), ganciclovir (GCV) and DHBT. Differences in binding modes between thymidine and GCV are shown in Figure 1.6 [25, 26].

Figure 1.5. X-ray structure of HSV1 TK (PDB ID: 2VTK)

Figure 1.6. Different binding modes of the natural substrate thymidine (A) and the most widely used anti-viral drug ganciclovir (B)
Additionally, careful analysis of the X-ray crystal structures of HSV1 TK with different ligands reveal that HSV1 TK active site is very flexible and adopts its conformation to maximize protein-ligand interactions (Figure 1.7).

![Figure 1.7. Different conformations of the HSV1 TK active site with thymidine (A), ganciclovir (B) and DHBT (C).](image)

These differences in substrate diversity between hTK and HSV1 TK are the crucial molecular basis for a wide field of possible applications [27]. Since HSV1 TK phosphorylates wider range of compounds than hTK it can be used for selective phosphorylation of the investigated compound \textit{in vivo}. However, almost all of the developed HSV1 TK substrates (several shown in Figure 1.8) have several disadvantages such as cytotoxicity, unfavorable pharmacokinetics, and by-stander effect.

![Figure 1.8. Developed HSV1 TK substrates for gene therapy monitoring [28]](image)
1.2.4 Anti-Herpes Viral Therapy

In order to be effective, antiviral agents must be capable of reaching the infected organ(s) and preventing viral replication without affecting the function of the host cell. As previously stated, HSV1 TK has broader substrate acceptance than hTK. Compounds like aciclovir (ACV), penciclovir (PCV) and ganciclovir (GCV) are exclusively phosphorylated only by HSV1 TK (Figure 1.9). Subsequently, di- and triphosphorylated analogues are formed by cellular enzymes which, in turn, block the viral replication process by terminating DNA elongation at the viral DNA polymerase [29].

![Figure 1.9 Most widely used anti-herpes viral agents.](image)

1.2.5 Gene Therapy

Gene therapy is a technique for correcting defective genes responsible for the disease development. In other words, it is the insertion of genes into an individual's cells and tissues to treat a disease and hereditary diseases by complementing a defective mutant allele with a functional one. There are several approaches for correcting faulty genes:

- A normal gene may be inserted into a non-specific location within the genome to replace a non-functional gene (the most common approach).
- An abnormal gene could be swapped for a normal gene through homologous recombination.
- The abnormal gene could be repaired through selective reverse mutation, which returns the gene to its normal function.
- To alter the regulation (the degree to which a gene is turned on or off) of a particular gene.
A carrier molecule, vector, must be used to deliver the therapeutic gene to the patient's target cells or tissue. The most common vector is a genetically modified virus to carry normal human DNA. Viruses are preferred means of carrier due to their ability to encapsulate and deliver their genes to human cells. Some of the different types of viruses used as gene therapy vectors are modified retroviruses, adenoviruses, adenoassociated viruses and herpes simplex viruses. In addition to virus-mediated gene-delivery systems, there are several non-viral options for gene delivery. They include delivery of naked DNA via plasmid, oligonucleotides, lipoplexes and polyplexes.

1.3 *In vivo* Imaging of Gene Expression

1.3.1 Reporter Gene Constructs

Reporter gene is a gene that is attached to a gene of interest (usually therapeutic gene) to monitor its activity. Several genes are chosen as reporter genes since they could easily be identified and measured, or because they are selectable markers. Reporter genes are used to indirectly provide the information whether a gene of interest is being expressed, as well as, the duration and the position of the expression. It is crucially important that a gene of interest and a reporter gene are simultaneously expressed, since only simultaneous expression of both genes can provide an accurate information on expression of gene of interest. In our case, HSV1 tk serves both as a gene of interest and as a reporter gene.

1.3.2 Available Technologies

There are several technologies which could be used to monitor gene expression in vivo: fluorescent imaging (FLI), bioluminescence imaging (BLI), single photon emission computed tomography (SPECT) and positron emission tomography (PET). Some of the characteristics of these imaging technologies are summarized in Table 1.2.
Table 1.2. Properties of several non-invasive in vivo imaging modalities of gene expression [30]

<table>
<thead>
<tr>
<th>Imaging modality</th>
<th>Form of energy used</th>
<th>Spatial resolution (mm)</th>
<th>Acquisition time per frame (s)</th>
<th>Molecular probe mass required (ng)</th>
<th>Molecular sensitivity (mol/l)</th>
<th>Tissue penetration depth (mm)</th>
<th>Mainly small animal or clinical?</th>
<th>Signal quantification capabilities</th>
<th>Cost (equipment and usage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLI</td>
<td>Visible to infrared light</td>
<td>2–10</td>
<td>10–2,000</td>
<td>$10^3$ – $10^6$</td>
<td>$10^{-9}$ – $10^{-11}$*</td>
<td>1–20</td>
<td>Small animal</td>
<td>Low–medium</td>
<td>Low</td>
</tr>
<tr>
<td>BLI</td>
<td>Visible to infrared light</td>
<td>3–10</td>
<td>10–300</td>
<td>$10^3$ – $10^6$</td>
<td>$10^{-13}$ – $10^{-16}$*</td>
<td>1–10</td>
<td>Small animal</td>
<td>Low–medium</td>
<td>Low</td>
</tr>
<tr>
<td>SPECT</td>
<td>Gamma rays</td>
<td>0.5–5</td>
<td>60–2,000</td>
<td>1–100</td>
<td>$10^{-10}$ – $10^{-11}$</td>
<td>$&gt;300$</td>
<td>Both</td>
<td>Medium–high</td>
<td>Medium–high</td>
</tr>
<tr>
<td>PET</td>
<td>Annihilation photons</td>
<td>1–4</td>
<td>1–300</td>
<td>1–100</td>
<td>$10^{-11}$ – $10^{-12}$</td>
<td>$&gt;300$</td>
<td>Both</td>
<td>High</td>
<td>High</td>
</tr>
</tbody>
</table>

**Fluorescence Imaging (FLI)**

Green fluorescent protein (GFP) is a perfect example of the “fluorescence imaging target” which was first isolated from the jellyfish *Aequorea Victoria*. GFP comprises of 11 β-sheets and a single α-helix containing the chromophore [31, 32] (Figure 1.10). It possesses unique property to fluorescent green when exposed to blue light which enables to monitor cellular processes in animals transparent to light [33, 34]. In other subjects, green fluorescence is efficiently absorbed by tissues limiting the usage of GFP only to qualitative observations for subcutaneous tissues up to depth of 3-4 mm.

**Bioluminescence Imaging (BLI)**

Bioluminescence imaging exploits the emission of visible photons at specific wavelengths on the basis of energy-dependent reactions catalyzed by luciferases. Luciferase genes have been cloned from several organisms, including bacteria, firefly (fluc, from *Photinus pyralis*) and a coral (rluc, from *Renilla*) [35] (Figure 1.11). A photon is produced by the oxydation of luciferin in the presence of ATP.
Spontaneous rate of the this reaction is extremely slow. However, if the reaction is catalyzed by the luciferase, the rate of the reaction increases several folds. The reaction takes place in two steps:

\[ \text{Luciferin} + \text{ATP} \rightarrow \text{luciferyl adenylate} \ + \ PP_i \]

\[ \text{Luciferyl adenylate} + \text{O}_2 \rightarrow \text{oxyluciferin} + \text{AMP} + \text{photon} \]

Luciferin and luciferase are not specific molecules, but are generic terms used to describe a substrate and its associated enzyme (or protein) that catalyzes a photon-producing reaction. The gene for luciferase is incorporated into DNA of cells or animal model of disease. In case ATP is available for the enzyme, the result is emission of photons that can be used to monitor cellular and genetic activity of every cell that expresses luciferase enzyme [35, 36]. Emitted photons can be detected and counted using low-light charge-coupled device (CCD) or photon-counting cameras.

**Single-Photon Emission Computed Tomography (SPECT)**

Molecular imaging using SPECT requires a molecular probe that is labeled with a radionuclide that results in the emission of gamma-ray or high-energy X-ray photons. In contrast to PET, only one photon is emitted making the determination of LORs and photon quantification in SPECT more difficult than in PET (Figure 1.12). Most common radionuclides used in SPECT are $^{123}$I, $^{111}$In and $^{99m}$Tc.

**Positron Emission Tomography (PET)**

As mentioned in Chapter 1.1, PET is based on the simultaneous detection of two gamma rays emitted during the annihilation process. Possibility of quantification of the radioisotope in the ROI makes PET an excellent modality for monitoring biological processes *in vivo*. Example of PET instrument is shown on Figure 1.13.
1.3.3 HSV1 TK PET Reporter Probes

PET reporter genes encode proteins that are either receptors that bind and sequester “positron-emitting PET reporter ligand probes” or enzymes that metabolize “PET reporter substrate probes” to sequestered products [37, 38].

The HSV1 tk gene has its roots in a therapeutic approach as a suicide gene, since it is less substrate specific than hTK and phosphorylates not only thymidine, but also a wide range of nucleoside analogues by activating them in situ to drugs. After the phosphorylation of a substrate, negatively charged formed metabolite remains trapped inside the transduced cells. Thus a specific signal, derived from the trapped radiolabeled reporter probe, provides an indirect measurement of transgene expression (Figure 1.14).

![Diagram of PET reporter gene approach](image)

**Figure 1.14**: Schematic illustration of a reporter gene approach. Initially, an imaging reporter gene has to be introduced into the cell. Transcription of the imaging reporter gene (HSV1 tk) with subsequent translation of the mRNA leads to the expression of an enzyme HSV1 TK. HSV1 TK can selectively phosphorylate reporter probe, which due to the negative charge stays trapped inside the cell. The imaging reporter probe will be phosphorylated in tk transfected cells only, while in non-transfected cells, the probe should freely move in and out of the cell. Thus the signal obtained from the reporter probe should be cell type specific, providing an indirect measurement of transgene expression.
1.4 Molecular Modeling

1.4.1 Introduction

Molecules, like all other objects that surround us have three dimensions (3D). Properties of the molecule are set by the position of its atoms in the space. Good examples are biological systems where the activity of an enzyme depends on its conformation. Since, the structure of the active site is well defined, the main condition any molecule must possess to be a substrate of certain enzyme is the ability to fully or partially enter the enzyme’s active site. Development of computers and computational methods gave us the opportunity to simulate a part of the biological system on computer. When enzyme structure and the position of its active site are known, we can estimate the complementarity between the ligand and the macromolecule. The first step is the determination of the geometric structure of the selected molecule, followed by the simulation and calculation to determine whether the selected molecule will be a good substrate or not.

Determination of the geometric structure can be made most precisely with X-Ray structural analysis of a crystal, while 3D structure of a molecule can be determined using theoretical approaches such as quantum-chemical \textit{ab initio}, semi-empirical methods and molecular mechanics.

1.4.2 Molecular Mechanics

Molecular mechanics treats molecules applying laws of classical physics on atomic nuclei, while electrons are neglected. This approach can be even more simplified in the explanation that molecular mechanic treats atoms as solid balls, bonds as harmonic oscillators, while non-bonding interactions are described by potential functions derived from classical mechanics. Molecular mechanics describes the energy of a system by a set of functions of potential energy applied from classical mechanics, which together with parameters used for their scoring are called “force fields”. Many force fields have been developed during the years which in general term for energy of the molecule

\[ E_{\text{sum}} = E_{\text{stretch}} + E_{\text{bend}} + E_{\text{torsion}} + E_{\text{non-bonding interactions}} \]
add certain values for specific types of molecules, increasing the accuracy of the model. Especially interesting force field is MMFF94, developed as combined field for organic molecules and proteins, and parameterized on large number of different chemical systems. These characteristics make application of MMFF94 suitable to different types of molecules [39]. Beside previously mentioned energy terms, which are used in all force fields, MMFF94 uses extra interaction energy between bond stretching and bending, energy outside the plane, van der Walls interaction energy and electrostatic interactions for better accuracy [40].

Conformational space of the molecules can be explored by random search (RS) method which is used for finding molecule’s global energy minimums [41-43]. Exploration of the conformational space is done by random changes of torsion angles inside the molecule, after which energy minimization follows. This cycle is repeated certain number of times. After each cycle, the obtained conformation is compared with those previously calculated: the new conformation is saved, while previously encountered ones are counted how many times they appeared [44]. It is important to emphasize that high energy conformations are discarded. Random search method is a very powerful tool for finding the minimum energy conformations because it is about an order of the magnitude more efficient than using dynamics for that purpose [45].

1.4.3 Docking

The docking process involves the prediction of ligand conformation and orientation (or posing) within a targeted binding site [46]. It is generally devised as a multi-step process in which each step introduces one or more additional degrees of complexity [47]. The process begins with the application of docking algorithms that pose small molecules into active site. Posing is the process of determining whether a given conformation and orientation of a ligand fits the active site [46]. The process itself is challenging since even relatively simple organic molecules can contain many conformational degrees of freedom. Algorithms are complemented by scoring functions that are designed to predict the biological activity through the evaluation of interactions between compounds and potential targets. Pre-selected conformers are usually additionally evaluated using more complex scoring schemes with more detailed treatment of electrostatic and van der Waals interactions, as well as inclusion of salvation or entropic effects [48].
Challenges to accurately predict binding conformations and compound activity include limited resolution of crystallographic targets, inherent flexibility, induced fit or other conformational changes that occur on binding and the participation of water molecules in protein-ligand interactions. Many docking programs have been developed in recent years. The most commonly used ones are DOCK, FlexX, AutoDock, GOLD which differ in used algorithms and scoring functions.

The choice of the docking program was made based on a study of Kellenberger et al. (2004) [49] stating that both the capacity of reproducing the X-ray pose (accuracy) as well as the discrimination of known thymidine kinase ligands was best with GOLD. GOLD (Genetic Optimisation for Ligand Docking) is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein. Additionally, it satisfies the fundamental requirement that the ligand must displace loosely bound water on binding [50]. GOLD performs automated docking with full acyclic ligand flexibility, partial cyclic ligand flexibility and partial protein flexibility in the neighborhood of the protein active site. In order to search the space of available binding modes efficiently, hydrogen bond motifs have been directly encoded into the genetic algorithm. A scoring function was used to rank generated binding modes. This comprised a term for hydrogen bonding (which took account of the fundamental requirement that water must be displaced from both donor and acceptor before a bond is formed); a pair wise dispersion potential that was able to describe a significant contribution to the hydrophobic energy of binding; and a molecular mechanics term for the internal energy of the ligand.
1.5 References


1 Introduction


1 Introduction


[26] Protein Data Bank (PDB) ID: 2VTK


[41] Saunders M., U.S. Patent 4,855,931


[43] Li Z and Scheraga HA, Monte Carlo-minimization approach to the multiple-minima problem in protein folding. Proc Natl Acad Sci USA;1987;84:6611-6615


[48] Gohlke H, Klebe G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed 2002;41:2644–76

Aim and Scope of This Study

Several imaging modalities, such as optical, magnetic resonance and radionuclide-based techniques are currently under investigation as tools for gene therapy monitoring in living subjects. Positron Emission Tomography (PET) is a radionuclide-based imaging modality which allows non-invasive, repetitive and quantifiable imaging of biological processes with highest available sensitivity. The most studied system for the visualization of the gene expression in animals and humans is Herpes Simplex Virus type 1 Thymidine Kinase (HSV1 TK), the enzyme product of the reporter gene HSV1 tk. Several pyrimidine and purine analogues labeled with F-18 or I-124 have been synthesized and evaluated as potential imaging agents for HSV1 TK expression in vivo. However, almost all of the reporter probes, including the most commonly used 18F-9-[4-fluoro-3-(hydroxymethyl)butyl]guanine ([18F]FHBG), have several disadvantages such as cytotoxicity, unfavorable pharmacokinetics, and by-stander effect. Due to the broad substrate acceptance, HSV1 TK phosphorylates both purine and pyrimidine classes of compounds to their corresponding monophosphates which are metabolically trapped inside the transfected cells. The major advantage of pyrimidine derivatives over purine ones is that pyrimidine analogues do not show any or a very low by-stander effect.

An ideal reporter probe for monitoring the gene expression should have the following characteristics:

1. High $V_{max}/K_i$ for HSV1 TK and good catalytic efficacy ($K_{cat}>0.1$ s-1).
2. The reporter probe should be stable in vivo and not be converted to peripheral metabolites that complicate the development of a quantitative assay.
3. The reporter probe should be cleared rapidly from the blood and non-specific sites. Additionally, it should preferably have an elimination route that does not interfere with the detection of a specific signal.
4. When the reporter gene is not expressed, there should be no significant accumulation of reporter probe in cells.
5. The reporter probe should be conveniently radiolabeled with an appropriate PET radioligand without significant changes in its properties, and should be labeled with an appropriate specific activity.
6. The reporter probe or its metabolites should not be cytotoxic at the concentrations used.
In a previous work a series of new C-6 substituted pyrimidine derivatives as HSV1 TK substrates was identified. Initial experiments suggested that these novel compounds do not exhibit cytotoxicity and show better *in vitro* binding affinities for HSV1 TK than already existing PET reporter probes. When labeled with appropriate PET radionuclide, such as $^{18}$F, these new analogues could be useful as PET reporter probes for monitoring HSV1 tk gene expression *in vivo*.

One such C-6 substituted pyrimidine derivative which was identified through the random synthesis is DHBT. A close analogue of DHBT, 6-(2-hydroxy-hydroxypropyl)-5-$^{18}$F-fluoromethyl (1H,3H)-pyrimidine-2,4-dione ($^{18}$FFluoromethyl HHT) was synthesized and evaluated for suitability as a PET reporter probe *in vivo*. Although $^{18}$FFluoromethyl HHT was superior to $^{18}$FHBG in terms of specificity of the accumulation in TK+ vs. TK- cells, $^{18}$FFluoromethyl HHT lacked *in vivo* stability.

The aim of this study is to synthesize novel non-cytotoxic fluorinated DHBT analogues and their respective precursors for radiolabeling with F-18 for PET imaging. Specifically, two new compounds, FHBT and N-Methyl DHBT, were selected based on the results obtained from docking studies. The new compounds should be evaluated *in vitro* to estimate their suitability as PET imaging agents for monitoring HSV1 tk expression *in vivo*.
2 Synthetic Approaches Toward FHBT
2.1 Introduction

After the ground-breaking work by Tjuvajev et al. in 1995 [1], numerous groups worldwide started the development of radiolabeled substrates for Herpes Simplex Virus 1 thymidine kinase (HSV1 TK), thus focusing research on non-invasive gene expression monitoring in vivo using positron emission tomography (PET). To be considered a suitable TK substrate for PET imaging a compound has to fulfill several requirements [2]:

- Good catalytic efficacy ($K_{cat}$);
- High specificity towards the HSV1-TK enzyme;
- Low cytotoxicity in normal and TK-transfected cells;
- Suitable structure for radiolabeling, and
- Favorable pharmacokinetics.

![Figure 2.1: List of most successful HSV1 TK analogues developed for gene therapy monitoring by PET [1]](image_url)
Target compounds developed since 1995 can be divided into two main groups: purine-type nucleoside analogues; and pyrimidine-type nucleoside analogues. Although several hundreds of TK substrates have been successfully synthesized, most of them failed in vitro or in vivo validation. Additionally, even the most successful ones (listed in Figure 2.1) have numerous disadvantages such as very slow pharmacokinetics, cytotoxicity and, the most common one, unspecific cell uptake [3].

We have decided to take an innovative approach to prepare a series of C-6 substituted pyrimidine derivatives (Figure 2.2) and to test their suitability as PET imaging agents for gene expression monitoring. The lead compound should preferably have two free hydroxyl groups; one to be replaced by a fluorine atom and the second for the phosphorylation by HSV1 TK.

![Figure 2.2:](image)

**Figure 2.2:** A: Purine derivatives; B: N-1 substituted pyrimidine derivatives, C: C-6 substituted pyrimidine derivative, DHBT

The lead structure, DHBT, was discovered in random reaction between thymine and several alcohols induced by gamma irradiation. Since it was proven by enzyme kinetics that DHBT is indeed a TK substrate, a lot of effort was made to develop a total synthesis of the compound whereby an overall yield of around 2.5% was obtained. To be useful as a PET tracer, DHBT has to be additionally modified in a way that one of its two hydroxyl groups is substituted by fluorine (Scheme2.1).

![Scheme 2.1:](image)

**Scheme 2.1:** Lead molecule DHBT and its fluoro derivative FHBT
Some attempts were made to obtain FHBT [4], and one such attempt is shown in Scheme 2.2.

Scheme 2.2: Synthetic scheme of a previous attempt to prepare FHBT which was unsuccessful due to intramolecular cyclization; Reagents and conditions: (i) Bu₂SnO/toluene, AcCl/THF-CH₂Cl₂; (ii) TsCl, pyridine; (iii) MsCl, pyridine

AJ 1 was used as a starting point for the preparation of FHBT. It was treated with dibutyl tin oxide to give the cyclic cyclostannioacetate intermediate which in a subsequent reaction with acetyl chloride gave the mono-acetylated compound AJ 2 in 49% yield. Reaction of AJ 2 with either tosyl chloride or mesyl chloride did not lead to the expected sulfonate AJ 3. Instead of AJ 3, a bicyclic compound AJ 4 was formed. Consequently, in this work new synthetic strategies were sought.
2. Synthetic Approaches Toward FHBT

2.2 Novel Synthetic Strategies to FHBT

2.2.1 Optimization of DHBT Synthesis

As mentioned earlier, the overall yield of DHBT was 2.5%. Therefore, initially it was necessary to improve on the yield of DHBT prior to introducing novel synthetic strategies towards the synthesis of FHBT. Special focus was on increasing the yield of reaction steps i, iv, vii and viii, (Scheme 2.3) since these steps were critical for the overall reaction yield. In step i, recrystallization was omitted and the crude product was used for the next reaction step in which dimethoxy compound 3 was prepared. As indicated in Scheme 2.3, the reaction yield for the first two steps increased from 56% to 95%. Corey oxidation was used in step iv to convert secondary hydroxide 5 into ketone 6. By simply using column chromatography instead of recrystallization, an increase of 10% in the yield of compound 6 was achieved. For the radical deoxygenation in step vii, schlenk line was used, which allowed almost a 2-fold higher yield (from 25% to 45%). The best condition for the deprotection of benzyl groups was found by extending reaction time from 2 to 3 hours after which the reaction went to completion. Compound 10 was obtained in 90% yield after column chromatography. Other reactions used in the pathway remained the same, or were only slightly modified. As a result of these optimized synthetic procedures, the overall reaction yield was increased 10-fold, from 2.5 to 25%.
Scheme 2.3: Synthetic pathway toward lead molecule, DHBT with initial (black) and optimized (red) reaction yields; Reagents and conditions: (i) POCl₃, reflux; (ii) NaOCH₃, MeOH; (iii) LDA, THF; (iv) N-Chlorosuccinimide, Et₃N, Toluene; (v) -55°C, THF; (vi) C₆H₅ClO₃, DMAP, CH₃CN; (vii) Bu₃SnH, AIBN, Toluene; (viii) -78°C, BCl₃, CH₂Cl₂; (ix) AcCl, H₂O; (x) NH₃, MeOH.
2.2.2 Synthetic Strategies Towards FHBT

For the design of the synthesis of FHBT, several key issues have to be taken into consideration:

1. **Solubility of the starting material**
   DHBT is highly soluble in water; partly in methanol, dioxane and DMSO. Therefore a limited choice of reaction solvents is available for the preparation of the intermediates of FHBT. As a consequence, acetylated compound 11 and dimethoxy compound 10 (Scheme 2.4) were additionally selected as starting compounds due to their sufficient solubility in organic solvents.

2. **Suitability of reagents**
   The choice of appropriate reagents was especially crucial when starting from compound 10 and 11 since both compounds contain protecting groups (two methoxy groups in compound 10 and two acetyl groups in compound 11) and their stability is of great importance for subsequent reactions.

![Scheme 2.4: Possible synthetic pathways toward FHBT](image-url)
2.2.3 Synthetic Strategies via Cyclic Sulfate

Cyclic sulfates have been used as precursors for the synthesis of fluorinated compounds [5-8]. These sulfates could be obtained via the corresponding sulfite followed by the oxidation with potassium permanganate, or directly with sulfuryl chloride [9-14]. We adopted a similar strategy for the preparation of FHBT (Scheme 2.5).

![Scheme 2.5. Proposed synthetic approach via cyclic sulfate](image)

Starting from compound 10, several reaction conditions (Table 2.1) were tried, but unfortunately no traces of the sulfate TIM 1 were found.

Table 2.1: List of reaction conditions used for the preparation of cyclic sulfate

<table>
<thead>
<tr>
<th>Temperature</th>
<th>Reaction time</th>
</tr>
</thead>
<tbody>
<tr>
<td>rt</td>
<td>0.5h, 2h, 24h, 48h</td>
</tr>
<tr>
<td>-78°C gradually to rt</td>
<td>15 min, 30 min, 60 min</td>
</tr>
<tr>
<td>-35°C gradually to 0°C</td>
<td>1h, 3h, 24h</td>
</tr>
<tr>
<td>0°C (constant)</td>
<td>0.5h, 1.5h, 2h, 3h</td>
</tr>
</tbody>
</table>

Additionally, we tried to prepare sulfite TIM 2, but when treated with thionyl chloride, compound 10 decomposed.
2.2.4 Synthetic Strategies using Direct Fluorination with DAST

Direct fluorination with DAST would provide another quick and convenient method for the preparation of FHBT (Scheme 2.6) [15-23]. The reaction of 10 with DAST was tried using different conditions (Table 2.2), however all attempts were futile since no fluoro intermediate TIM 4 was formed.

![Scheme 2.6. Synthetic approach with DAST starting from compound 10](image)

Compound 10 either decomposed or the isolated products did not correspond to the target compound.

<table>
<thead>
<tr>
<th>Temperature</th>
<th>Reaction time (in min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-78°C (constant)</td>
<td>25</td>
</tr>
<tr>
<td>-78°C and gradually warming to rt</td>
<td>15, 30, 60</td>
</tr>
</tbody>
</table>

2.2.5 Synthetic Strategies using Protecting Groups

After several unsuccessful attempts to prepare FHBT from compound 10, new synthetic strategies were proposed starting from acetylated compound 11. The synthetic pathway, as shown on Scheme 2.7 involves the following steps:

1. Protection of the –NH groups
2. Selective removal of the acetyl groups
3. Fluorination with DAST
4. Removal of the N-protecting groups
Protection of $\text{–NH}$ functionality with $p$-methoxybenzyl (PMB) protecting group is well described in the literature [24-34]. For our purposes, the best approach was found in the publication by Smith et al. [25] since it was shown that PMB group could be selectively cleaved or retained in compounds with similar structure. However, treatment of 11 with PMB-Cl using conditions described by Smith et al., did not lead to the expected compound (Scheme 2.8). Similar results were obtained with benzyloxycarbonyl (Cbz) protecting group (Scheme 2.8).

Successful protection with tert-butoxycarbonyl (Boc) group was achieved using the procedure developed by Martin et al. [35] for the synthesis of $[^{18}\text{F}]\text{FLT}$. Compound 13 (Scheme 2.9) was obtained in 94% yield after column chromatography purification.
After the successful preparation of the Boc protected compound 13, the next step was to selectively remove the acetyl groups making two hydroxyl groups available for possible modification. Detailed literature search suggested that the acetyl group should not be stable under slightly basic conditions (pH=7-10), while the Boc group should be stable [36-40]. However, instead of the acetyl groups, deprotection of the Boc groups occurred. Such an outcome was not favorable since the reaction led to compound 11 (Scheme 2.10). By extending the reaction time, both acetyl groups were slowly cleaved from the molecule and the final compound was, in fact, DHBT (Scheme 2.10). The progress of the reaction was followed by HPLC and the products were analyzed by MS and $^1$H NMR. The results obtained by $^1$H NMR confirmed that the Boc group was cleaved much faster from N-3 than N-1 position. Reaction conditions used for the hydrolysis are shown in Table 2.3.

**Scheme 2.9:** Reaction of compound 11 with Boc$_2$O

**Scheme 2.10:** Deprotection of Boc and acetyl groups of compound 13
2. Synthetic Approaches Toward FHBT

<table>
<thead>
<tr>
<th>Base</th>
<th>Solvent</th>
<th>Temperature</th>
<th>Reaction time</th>
</tr>
</thead>
<tbody>
<tr>
<td>NH₃</td>
<td>MeOH</td>
<td>rt</td>
<td>1h, 2h, 3h</td>
</tr>
<tr>
<td>0.1 M NaOH</td>
<td>ACN</td>
<td>rt</td>
<td>0 min, 30 min, 60 min, 90 min, 100 min</td>
</tr>
<tr>
<td>NaOH(s)</td>
<td>ACN</td>
<td>rt</td>
<td>2 min, 60 min, 24 h</td>
</tr>
<tr>
<td>K₂CO₃</td>
<td>MeOH/H₂O</td>
<td>rt</td>
<td>30 min, 60 min, 90 min</td>
</tr>
<tr>
<td>-</td>
<td>H₂O</td>
<td>rt</td>
<td>0 min, 30 min, 60 min</td>
</tr>
</tbody>
</table>

A similar approach was used for the preparation of FHBT starting from compound 12 (DHBT). The synthetic strategy (Scheme 2.11) comprised of:

1. Selective protection of the –NH groups
2. Protection of the –OH and –NH groups with the same protecting group, followed by selective deprotection of hydroxyl groups, if step 1 fails
3. Fluorination using DAST or via introduction of the leaving group
4. Removal of the N-protecting groups

Scheme 2.11: Possible reaction pathways to FHBT from DHBT
The protection of DHBT with the PMB protecting group was performed using previously described procedures [24-34] however, no new traces of the desired compound were formed. The same result was obtained with the Cbz protecting group (Scheme 2.12) [41-54].

**Scheme 2.12:** Reaction of DHBT with PMB-Cl and CBZ-Cl

Generally, for the Boc protecting group it was not clear whether selective cleavage from the –OH groups would be feasible. The literature [55-61] suggested that the –NH groups should be more reactive than –OH groups, but this turned out not to be the case.

The reaction of DHBT with 2 equivalents of Boc₂O gave exclusively compound 14 (Scheme 2.13). The selective protection of both hydroxyl groups and the presence of two free –NH groups were confirmed by ¹H NMR. Resonance peaks at 9.6 and 10.4 ppm corresponded to unprotected N-1 and N-3 amino groups, respectively. When DHBT was treated with 6 equivalents of Boc₂O, the tetra-Boc-protected compound 16 was obtained (Scheme 2.13). The reaction was followed by HPLC and each component of the reaction mixture was isolated and analyzed by ¹H NMR. Immediate formation of intermediate 14 was observed. This was followed by the formation of compound 15 and finally the tetra-Boc-protected product 16.

**Scheme 2.13:** Reaction of DHBT with Boc₂O
Unfortunately, neither compound 14 nor compound 16 could be used in subsequent synthetic steps since the Boc protecting group turned out to be more stable on –OH than on –NH functionalities.

As a last possibility, we examined the synthetic strategy shown in Scheme 2.14. The strategy involved:
1. Selective protection of one hydroxyl group with R₃
2. Fluorination
3. Removal of protecting group R₃

![Scheme 2.14: Synthetic strategy involving the selective protection of one hydroxyl group starting from DHBT](image)

MTr-Cl (4-Methoxytrityl chloride) is a protecting group used in the synthesis of [¹⁸F]FHBG [34]. It is generally stable under fluorination conditions and does not require harsh deprotecting conditions [35, 62-64]. The reaction of DHBT with MTr-Cl successfully gave compound 17 in 54% chemical yield (Scheme 2.15).

![Scheme 2.15: Reaction of DHBT with MTr-Cl](image)

Direct fluorination of 17 was successfully achieved by reaction with DAST to produce the fluorinated intermediate 18. However, deprotection of the MTr group using 5% HCl in methanol failed to produce the expected results. This is possibly due to decomposition or intramolecular cyclization of intermediate 18 (Scheme 2.16). Evidence for decomposition was obtained from HPLC analysis, while evidence for intramolecular cyclization was obtained by ¹H NMR from the isolated product.
2. Synthetic Approaches Toward FHBT

![Reaction of compound 17 with DAST and deprotection with HCl](image)

Scheme 2.16: Reaction of compound 17 with DAST and deprotection with HCl

In one case, a trace of a compound potentially corresponding to FHBT was detected when the reaction was followed by HPLC. This was based on the retention time and the absorption pattern observed within the reaction mixture (Figure 2.3).

![Diode array chromatogram showing different retention times and same absorption pattern of (A) DHBT; and (B) possible FHBT](image)

Figure 2.3: Diode array chromatogram showing different retention times and same absorption pattern of (A) DHBT; and (B) possible FHBT

Another synthetic approach was to introduce a good leaving group such as the trifluoromethanesulfonate functionality which would be substituted for fluorine in an $S_{N}2$-type reaction (Scheme 2.17), but for unknown reasons this strategy also failed.

![Reaction of 17 with Tf₂O](image)

Scheme 2.17: Reaction of 17 with Tf₂O

Finally, it was possible to prepare compound 19 (Scheme 2.18) after the catalytic amount of trimethylamine hydrochloride was added to the reaction mixture.
2. Synthetic Approaches Toward FHBT

Scheme 2.18: Synthesis of the tosyl intermediate 19

By preparing compound 19, a very important milestone was achieved since it could be used for the preparation of “cold reference” compound FHBT by reaction with TBAF. Additionally, compound 19 could be used as a precursor for the radiolabeling of $^{18}$F-labeled FHBT.

Scheme 2.19: Reaction of tosylated compound 19 with TBAF

The reaction with TBAF unfortunately did not produce the desired fluorinated product 18 (Scheme 2.19). Compound 19 completely decomposed under the reaction conditions used.

2.3 Fluorine-18 Radiolabeling of $[^{18}$F$]$FHBT

Even though we were unsuccessful in preparing the reference compound, we decided to investigate whether radiolabeling with $^{18}$F would be feasible. The two questions to be answered were:

1. Would the radiofluorination step work with K2.2.2/$^{[18}$F$]$F complex and whether it would be possible to prepare compound 20 (Scheme 2.20)

2. If the radiolabeling of 19 was possible, what would be the fate of the intermediate 20 after the hydrolysis?
The radiolabeling (Scheme 2.20) was performed in acetonitrile at 90°C in a reaction time of 30 minutes. As indicated from HPLC chromatograms (Figure 2.4 and 2.5), the fluorination reaction with K2.2.2/[18F]F was successful. The desired intermediate 20 was produced with 10% conversion (Figure 2.6). However, attempts to cleave MTr group were not successful. An unknown compound was obtained in 6% conversion (Figure 2.5).

Scheme 2.20: Radiolabeling of compound 19
2. Synthetic Approaches Toward FHBT

Figure 2.4: UV and HPLC radio chromatograms of the reaction mixture after the fluorination of precursor 19

Figure 2.5: UV and HPLC radio chromatograms after the hydrolysis of intermediate 20
2. Synthetic Approaches Toward FHBT

2.4. Conclusion and Outlook

The synthetic pathway to lead molecule DHBT was optimized and the overall yield was increased 10-fold, i.e. from 2.5 to 25%. Several synthetic strategies starting from different compound failed to deliver the desired target compound FHBT. In most cases either the intermediates decomposed or an intramolecular cyclization was observed.

Although we successfully produced F-19 and F-18 fluoro derivatives of DHBT in the presence of MTr protecting group, neither FHBT nor $^{18}$F[FHBT was isolated.

A novel pathway toward FHBT that would be worth trying, is the one in which the fluorine atom is introduced at the very beginning of the synthesis (Scheme 2.21). The synthesis would start from commercially available glycerald (A1), which would be benzylated in one step. Benzylated intermediate A2 would be transformed into fluoro intermediate A3 with KHF$_2$. In analogy to Scheme 2.3, reference compound FHBT could be obtained in reasonable yield (Scheme 2.21).

A drawback of this approach is that it is only applicable for the preparation of the reference compound and cannot be used for the synthesis of radiolabeled FHBT. A possibility could be to use chlorine instead of fluorine. Chlorine could act either as a leaving group or could be converted to a sulfonate [65, 66]. With chlorine, intramolecular cyclization would be less probable since chloride is a poor leaving group.
Scheme 2.21: Synthetic approach in which fluorine atom is introduced in the early stage of the synthesis
2.5 Materials and Methods

The $^1$H NMR and $^{13}$C NMR spectra were recorded on a 300 MHz Varian Gemini 2000 or a Bruker 400 MHz spectrometer with trimethylsilane as an internal standard. Chemical shifts (δ) are reported in parts per million, and signals are expressed as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) or br (broad).

The samples were dissolved in DMSO-d$_6$, D$_2$O or CD$_3$OD and measured in 5mm NMR tubes. The $^1$H, $^{13}$C NMR chemical shift values (δ) are expressed in ppm referred to TMS and coupling constants (J) in Hz.

Mass spectroscopy analysis was performed with a Micromass Quattro micro TM API LC-ESI or a LCT Premier ESI-TOF from Waters.

TLC was done on Merck silica gel 60 F$_{254}$ precoated plates. Compounds were visualized under UV light (254 nm).

Silica gel used for column chromatography was Silica gel 60, particle size 0.040-0.063 mm (230-400 mesh ASTM), Fluka, Germany.

Evaporations were performed using Büchi Rotavapor R-215 system at 40°C.

Production of [$^{18}$F] fluoride: No-carrier-added aqueous [$^{18}$F]fluoride ion was produced on an IBA Cyclone 18/9 cyclotron by irradiation of 2.0 ml water target (for a large volume target) or 0.585 ml (for a small volume target), using a 18 MeV proton beam on 98% enriched [$^{18}$O]water by the [$^{18}$O(p,n)$^{18}$F] nuclear reaction.

HPLC 1 (analytical): Hitachi LaChrom Elite system equipped with UV diode array detector (DAD) and a column oven; column: analytical Merck LiChrospher C18 RP-18E, pore size: 100Å, particle size: 5 µm; flow rate: 1ml/min; temperature: 37°C; UV detection 220-400 nm.

HPLC analytical lab: Equipment: Agilent 1100 system equipped with a UV multi-wavelength detector; the radioactivity was monitored with a Raytest Gabi Star detector using a Gina software; column: analytical Merck LiChrospher RP-18E, pore size: 100Å, particle size: 5 µm; flow rate: 1ml/min; temperature: rt; UV detection at 254 nm.

HPLC 2 (analytical): Merck-Hitachi L6200A system equipped with UV multi-wavelength detector; column: analytical Merck LiChrospher RP-18E, Pore Size: 100Å, particle size: 5 µm; flow rate: 1ml/min; temperature: rt; UV detection at 254 nm or 275 nm.

HPLC 3 (semiprep): Merck-Hitachi system equipped with L6200A pump, Knauer variable wavelength detector and Eberline radiation monitor; column: semi-preparative Phenomenex Gemini C18, pore size: 110Å, particle size: 5 µm; flow rate: 5ml/min; temperature: rt; UV detection at 254 or 275 nm.
2,4-Dichloro-5,6-dimethylpyrimidine (2)
A mixture of 2,4-dihydroxy-5,6-dimethylpyrimidine 1 (6.33 g, 45 mmol) and POCl₃ (30 ml, 328 mmol) was heated under reflux for 4 h. Excess of POCl₃ was then removed under reduced pressure and the residue was added to ice, washed with ether and dried over sodium sulphate. The crude product was recrystallized from ethanol to give 2 (7.54 g, 94.3 %, mp 70-71 °C); (C₆H₆N₂Cl₂), Rf = 0.65 (n-hexane/EtOAc = 5/1).

¹H NMR (DMSO-d₆) 2.26 (s, 3H, CH₃); 2.47 (s, 3H, CH₃).

¹³C NMR (DMSO-d₆) δ 155.24 (C-2), 171.48 (C-4), 127.74 (C-5), 160.54 (C-6), 22.83 (CH₃), 14.40 (CH₃).

2,4-Dimethoxy-5,6-dimethylpyrimidine (3)
To a solution of sodium (2 g, 87.0 mol) in methanol (50 ml) was added 2 (7.54 g, 42.6 mmol). The reaction mixture was refluxed for 6 h. The solvent was evaporated and water was added to dissolve NaCl. The oily layer was extracted with dichloromethane, dried over sodium sulphate and concentrated under reduced pressure. The residue was kept in refrigerator and gave colorless crystals of 3 (7.10 g, 99.1 %, mp 39-40 °C).

¹H NMR (DMSO-d₆) 1.98 (s, 3H, CH₃); 2.29 (s, 3H, CH₃); 3.82 (s, 3H, OCH₃); 3.87 (s, 3H, CH₃).

¹³C NMR (DMSO-d₆) δ 162.10 (C-2), 168.67 (C-4), 107.25 (C-5), 165.67 (C-6), 53.96 (OCH₃), 53.74 (OCH₃), 21.46 (CH₃), 9.67 (CH₃).

1,3-bis(benzyloxy)propan-2-one (6)
N-Chlorosuccinimide (18.0 g, 134.8 mmol) was suspended in dry toluene (210 ml), and the mixture was cooled in dry ice bath. Dimethyl sulfide (15 ml, 204.2 mmol) was added, and the mixture was cooled to -25°C in a dry ice-CH₂Cl₂ bath. 1,3-bis (benzyloxy)-2-propanol 5 (25.0 g, 91.8 mmol) in toluene (21 ml) was added to the mixture, and the mixture was kept under argon for 4 h. Triethylamine (100 ml, 717.5 mol) was added, and the reaction was allowed to warm to rt. After 30 min of stirring at rt, the solution was passed through a filter paper. The residue was washed with diethyl ether (250 ml). The filtrate and the washings were combined, neutralized with 5% aqueous HCl to pH 7, washed with saturated NaCl solution (3 x 50 ml) and then with water (3 x 50 ml), and finally dried over sodium sulphate. The solvent was removed in vacuum, and the resulting oil was purified by column chromatography (n-hexane/EtOAc = 4/1) to give 13.5 g (54.4 % yield) of compound 6 (C₁₇H₁₈O₃). mp 40 °C.

MS m/z: 270 (M⁺).

¹H NMR (DMSO-d₆) 7.23 (10H, Ph); 4.46 (s, 4H, CH₂Ph); 4.13 (s, 4H, CH₂O).
2. Synthetic Approaches Toward FHBT

6-[[2-[1,3-bis(benzyloxy)-2-hydroxypropyl]methyl]-2,4-dimethoxy-5-methylpyrimidine (7)

LDA (1.5 M, 45 ml, 113 mmol) was added dropwise to a solution of 2,4 dimethoxy-5,6-dimethylpyrimidine 3 (7.50 g, 44.6 mmol) in THF (90 ml) at -70°C. The temperature was raised to -55°C, and the solution was stirred for 30 min. 6 (12.00 g, 44.4 mmol) in THF (65 ml) was added dropwise to this solution, and stirring was continued for 2.5 h while the temperature was maintained at -55°C. The solution was neutralized by the addition of AcOH to pH 7 and then the temperature was raised to 25°C, and the solvent removed. The residue was partitioned between AcOEt and H2O. The organic layer was separated, dried over sodium sulfate and removed by evaporation. The residue was chromatographed on silica gel column, eluting with n-hexane/EtOAc = 3/1. The desired fractions were concentrated in vacuum to afford compound 7 in 59% yield (1.25 g).

MS m/z: 439.3 (M+).

1H NMR (DMSO-d6) 7.28 (10H, Ph); 5.09 (s, 1H, OH); 4.48 (s, 4H, CH2Ph); 3.87 (s, 2H, CH2O); 3.76 (s, 3H, OCH3); 3.44 (s, 3H, OCH3); 2.83 (s, 2H, CH2); 1.99 (s, 3H, CH3).

6-(3-Benzyloxy-2-benzyloxymethyl-propyl) 2,4-dimethoxy-5-methyl pyrimidine (9)

Methyl oxalyl chloride (5.9 ml, 63.7 mmol) was added to a mixture of 6-[[2-[1,3-bis(benzyloxy)-2-hydroxypropyl]methyl]-2,4-dimethoxy-5-methyl-pyrimidine 7 (6.00 g, 13.7 mmol) and 4-(dimethylamino) pyridine (DMAP, 3.7 g, 29.6 mmol) in dry CH3CN (50 ml) at 0°C under argon. The mixture was stirred for 14 h under argon at rt and then diluted with EtOAc (400 ml). The mixture was washed successively with saturated aqueous NaHCO3 solution (120 ml) and H2O (120 ml). The separated organic phase was dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was coevaporated twice with dried toluene (40 ml) to afford the methyl oxalyl ester 8. MS m/z: 481 (M+).

A mixture of Bu3SnH (9.0 ml, 36 mmol) and 2,2’-azobis (isobutyronitrile) (AIBN; 180 mg) in dry toluene (50 ml) was added to a solution of 8 in dry toluene (130 ml) under an argon atmosphere. The mixture was heated at 110°C for 3 h and the solvent was removed by evaporation under reduced pressure. The residue was purified by column chromatography (mixture of n-hexane/EtOAc = 4/1 as mobile phase) to afford 2.77 g of 6-[3-benzyloxy-2-[[benzyloxy]methyl] propyl] thymine 9 in 48% yield.

MS m/z: 423.3 (M+).

1H NMR (DMSO-d6) 7.29 (10H, Ph); 4.42 (s, 4H, CH2Ph); 3.87 (s, 3H, OCH3); 3.79 (s, 3H, OCH3); 3.43 (d, 4H, OCH2); 2.68 (d, 2H, CH2); 1.97 (s, 3H, CH3).
6-(1,3-dihydroxy-isobutyl) 2, 4-dimethoxy-5- methyl pyrimidine (10).
A mixture of 9 (1.44 g, 3.4 mmol) in dry CH2Cl2 (20 ml) was cooled to −78°C. BCl3 (1M in CH2Cl2, 17.5 ml, 17.5 mmol) was added via syringe and under argon. The mixture was stirred at -78°C for 4h, and then the temperature was raised to -40°C. A mixture of CH2Cl2/MeOH (1/1; 60 ml) was added, and the cooling bath was removed. The solution was neutralized with saturated NaHCO3 solution to pH 7 and stirred for additional 30 min. The organic layer was separated and dried over magnesium sulfate. The solvent was removed under reduced pressure and then purified on a silica column (CHCl3/i-PrOH = 95/5) to give 0.64 g of compound 10 (77.9% yield).
MS m/z: 243.23 (M+).
1H NMR (CDCl3) 3.98 (s, 3H, CH3O); 3.94 (s, 3H, CH3O); 2.84 (d, 4H, OCH2); 2.08 (s, 3H, CH3); 2.04 (m, 2H, CH2).

2-((5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl)-propane-1,3-diyl diacetate (11)
A solution of 10 (2.5 g, 10.3 mmol) dissolved in acetyl chloride (10 ml) and containing a few drops of water was stirred at reflux 48 hrs after which was evaporated to dryness. Raw 11 was purified by column chromatography (mixture EtOAC/CH3OH=95/5) to afford 2.3 g of pure 11 (75% yield).
MS m/z= 299.01 (M+).
1H NMR (CDCl3) 10.72 (s, 1H, NH); 10.04 (s, 1H, NH); 4.13 (m, 4H, CH2O); 2.15 (s, 3H, CH3); 2.05 (s, 1H, CH2).

6-(1,3-dihydroxy-isobutyl)-thymine (DHBT) (12).
A solution of 10 (2.5 g, 10.3 mmol) dissolved in acetyl chloride (10 ml) and containing a few drops of water was stirred at reflux 48 hrs after which was evaporated to dryness. Residue was dissolved in saturated methanolic ammonia, stirred at rt for additional 4 h, and then evaporated to dryness. The product was collected and washed with EtOAc/MeOH = 95/5 to give pure DHBT in 75 % yield.
MS m/z: 215.1 (M+).
1H NMR (DMSO-d6) 7.28 (s, 1H, NH); 6.67 (s, 1H, NH); 3.40 (m, 4H, CH2O); 2.40 (d, 2H, CH2); 1.86 (s, 1H, CH); 1.75 (s, 3H, CH3)
13C NMR (DMSO-d6) δ 171.54 (C-2), 164.71 (C-4), 150.06 (C-6), 104.80 (C-5), 60.67 (C-3), 42.69 (C'-2), 29.03 (C'-1), 9.72 (CH3).
Di-tert-butyl 6-(3-acetoxy-2-(acetoxy methyl)propyl)-5-methyl-2,4-dioxopyrimidine-1,3(2H,4H)-dicarboxylate (13)
A solution of 11 (100 mg, 0.33 mmol) in dry pyridine (5.0 ml) was stirred at rt 10 minutes after which a solution of Boc₂O (220 mg, 1.0 mmol in 1.0 ml dry pyridine) was added dropwise to the reaction flask. Obtained mixture was additionally stirred at rt for 90 minutes and solvent was removed. Further purification by column chromatography (n-hexane/EtOAC=1/1) afforded 150 mg of pure 13 (94 % yield).
MS m/z: 521.24 (M + Na⁺)
\(^1\)H NMR (CDCl₃): 1.55 (d, 18H, Boc); 2.04 (d, 6H, Ac); 2.19 (s, 3H, CH₃); 2.89 (m, 2H, CH₂); 4.13 (m, 4H, CH₂+CH₂).

Tert-butyl 2-((5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl)propane-1,3-diyl dicarbonate (14) (DHBT+2 Boc)
A solution of 12 (23.0 mg, 0.11 mmol) in dry pyridine (5.0 ml) was stirred at rt 10 minutes after which a solution of Boc₂O (53.9 mg, 0.24 mol in 0.5 ml dry pyridine) was added dropwise. Obtained mixture was additionally stirred at rt for 1.5 hrs and solvent was removed. Purification by column chromatography (pure EtOAC) afforded 31.2 mg of pure 14 in 72% yield.
MS m/z: 415.16 (M⁺)
\(^1\)H NMR (CDCl₃): 10.4 (1H, NH); 9.62 (1H, NH); 4.13 (s, 2H, CH₂O); 4.11 (s, 2H, CH₂O); 2.61 (m, 1H, CH); 1.90 (s, 3H, CH₃); 1.47 (m, 18H, CH₃).

Di-tert-butyl 6-(3-(tert-butoxycarbonyloxy)-2-((tert-butoxycarbonyloxy)methyl)propyl)-5-methyl-2,4-dioxopyrimidine-1,3(2H,4H)-dicarboxylate (16) (DHBT+4 Boc)
A solution of 12 (22.3 mg, 0.10 mmol) in dry pyridine (1.0 ml) was stirred at rt 10 minutes after which a solution of Boc₂O (134 mg, 0.61 mmol in 0.3 ml dry pyridine) was added dropwise. Obtained mixture was additionally stirred at rt for 1.5 hrs and solvent was removed. Further purification by column chromatography (n-hexane/EtOAC=5/2) afforded 39.4 mg of pure 16 in 62% yield.
MS m/z: 615.34 (M⁺)
\(^1\)H NMR (CDCl₃): 4.15 (s, 2H, CH₂O); 4.13 (s, 2H, CH₂O); 2.89 (m, 1H, CH); 2.17 (s, 3H, CH₃); 1.55 (m, 9H, CH₃); 1.54 (m, 9H, CH₃); 1.47 (m, 18H, CH₃).
6-(3-Hydroxy-2-(((4-methoxyphenyl)diphenylmethoxy)methyl)propyl)-5-methylpyrimidine-2,4(1H,3H)-dione (17)

A solution of 12 (5.0 mg, 23.3 μmol) in dry pyridine (1.5 ml) was stirred with 2.9 mg of DMAP (23.5 μmol) at rt for 10 minutes after which MTr-Cl was added (8.0 mg, 25.7 μmol). Obtained mixture was additionally stirred at 50°C for 1.5 hrs and solvent was removed. Further purification by column chromatography (CH3Cl/i-PrOH=9/1) afforded 4.1 mg of pure 17 in 36% yield.

MS m/z: 485.44 (M-)

1H NMR (CDCl3): 1.78 (s, 3H, CH3); 2.04 (s, 1H, CH); 2.57 (d, 2H, CH2); 3.18 (m, 2H, CH2); 3.74 (m, 2H, CH2); 3.76 (s, 3H, OCH3); 6.80-7.39 (m, 14H, Ph).

3-((4-Methoxyphenyl)diphenylmethoxy)-2-((5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl)propyl 4-methylbenzenesulfonate (19)

A solution of 17 (3.0 mg, 6.2 μmol), Me3N.HCl (0.1 mg) and Et3N (10 μL) in dry CH2Cl2 (0.5 ml) was stirred at rt 5 minutes after which a solution of Ts-Cl (1.4 mg, 7.4 μmol in 150 μL) was added dropwise. Obtained mixture was additionally stirred at rt for 1 hr and solvent was removed. Further purification by semi-preparative HPLC afforded 3.5 mg of pure 19 in 88% yield.

MS m/z: 611.13 (M+)

1H NMR (CDCl3): 1.90 (m, 1H, CH); 2.43 (s, 9H); 3.06 (m, 2H, CH2); 7.10-7.90 (m, 18H, Ph), 11.43 (s, 1H, NH).

6-(3-Fluoro-2-(hydroxymethyl)propyl)-5-methylpyrimidine-2,4(1H,3H)-dione (FHBT)

Solution of 17 (1.8 mg, 3.7 μmol) in dry CH2Cl2 (3 ml) under argon, was cooled down to -78°C and stirred for 15 min. (Dimethylamino)sulfur trifluoride (20μL, 151 μmol) was added dropwise and reaction was kept at -78°C for additional 15 min after which cooling was removed. After 45 min of stirring at rt, saturated aqueous solution of NaHCO3 was added (3 ml) and reaction was partitioned. Organic layer was separated and evaporated to afford 1.5 mg of raw 18 (83% yield).

Solution of raw 18 was dissolved in 5% HCl in CH3OH (1.5 ml) was refluxed 15 min at 90°C under argon after which the solvent was removed. Possible FHBT was purified using semi-preparative HPLC, however not in sufficient amounts for the analysis.
Radiolabeling of 3-((4-Methoxyphenyl)diphenylmethoxy)-2-((5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methyl)propyl 4-methylbenzenesulfonate (19)

To a 10-mL Pyrex brand tube with screw cap containing 5 mg Kryptofix 2.2.2 and 2 mg of K$_2$CO$_3$ was added 15 GBq $^{18}$F-fluoride. Water was azeotropically evaporated from the mixture using dry CH$_3$CN (3 x 1.0 mL) at 90°C under a stream of nitrogen. After the final drying sequence, 2 mg of 19 dissolved in 350 μl dry CH$_3$CN were added to the F-18 residue. The reaction was carried out at 90°C for 30 min. 300 μl of HCl (5% in CH$_3$OH) were added and the reaction was kept for 10 min at 90°C after which it was allowed to cool to rt. Water (4.7 ml) was added and the mixture was purified by HPLC. The fraction containing the F-18 labeled compound unfortunately did not correspond to $[^{18}$F]FHBT.
2.6 References


2. Synthetic Approaches Toward FHBT


[34] Horita K, Yoshioka T, Tanaka T, Oikawa Y, Yonemitsu O. On the selectivity of deprotection of benzyl, mpm (4-methoxybenzyl) and dmpm (3,4-dimethoxybenzyl) protecting groups for hydroxy functions. Tetrahedron 1986;42:3021-8


2. Synthetic Approaches Toward FHBT


[60] Horita K, Yoshioka T, Tanaka T, Oikawa Y, Yonemitsu O. On the selectivity of deprotection of benzyl, mpm (4-methoxybenzyl) and dmpm (3,4-dimethoxybenzyl) protecting groups for hydroxy functions. Tetrahedron 1986;42:3021-8


3 Development of a Novel C-6 Substituted Pyrimidinone Derivative for Gene Therapy Monitoring

(Manuscript prepared for publication)
1. Introduction

Non-fluorinated acyclic nucleoside analogues are known to be potent anti-herpes virus agents.[1] The most efficient ones, aciclovir (ACV) and ganciclovir (GCV) possess low host toxicity and are active against herpes simplex virus type 1 (HSV1) and 2 (HSV2) [1]. The selectivity of these acyclic nucleoside analogues is due, in part, to the fact that they are phosphorylated only in virus-infected cells, where a virus specific thymidine kinase of low substrate specificity converts the nucleoside analogues to their monophosphate derivatives. Fluoro derivatives of ganciclovir and penciclovir, i.e. 9-[(3-fluoro-1-hydroxy-2-propoxy)methyl]guanine (FGCV) and 9-(4-fluoro-3-hydroxymethyl-butyl)guanine (FPCV) were evaluated as tracers for non-invasive positron emission tomography (PET) imaging of herpes simplex virus type 1 thymidine kinase (HSV1 TK) gene expression [2,3]. To be considered a suitable agent for monitoring HSV-1 TK expression in vivo by PET, compound has to fulfill several requirements [4]: good catalytic efficacy for HSV1 TK, high specificity towards the HSV1-TK enzyme, low specificity toward other enzymes, low cytotoxicity in normal and TK-transfected cells, suitable structure for radiolabeling and favorable pharmacokinetics.

In a previous work, we described lead compound DHBT (Figure 1) and discussed its advantages [5]. The promising results obtained prompted us to pursue the development of a fluorinated derivative of DHBT (Figure 1) for evaluation as a ligand for monitoring HSV1 TK expression.

Herein we describe docking studies and the synthesis of the key compound N-Me DHBT (Figure 1), its binding affinity to HSV-1 TK, kinetic turnover constant and cytotoxicity in B16F1 cell lines. In addition, we report on the fluoro derivative preparation of N-Me DHBT, N-Me FFBT (Figure 1), as well as the fluorine-18 radiolabeling of [18F]N-Me FHB.

Figure 1. Structures of DHBT, N-Me DHBT and N-Me FHBT
2. Results and Discussion

Docking studies using GOLD

The choice of the docking program among the ones available in our lab (Autodock, Dock, Gold, FlexX) was made based on a study of Kellenberger et al. (2004) stating that both the capacity of reproducing the X-ray pose (accuracy) as well as the discrimination of known thymidine kinase ligands were best achieved with the docking program Gold [6].

Gold 2.2 (Genetic Optimisation for Ligand Docking) is especially suited for complexes displaying predominantly H-bonds [7]. Apart from visual inspection, the main parameter to estimate if the docking was successful is the fitness function, which has been optimised for the prediction of ligand binding positions rather than affinity.

Docking studies were performed in order to investigate whether N-Me DHBT would, indeed, be a substrate for HSV1 TK. The docking model was tested by examining binding modes of thymidine, penciclovir (PCV), ganciclovir (GCV) and DHBT. It was successfully validated since all binding modes corresponded to the binding modes seen in their respective crystal structures with HSV1 TK. Root mean square deviation (RMSD) values were always close to 1 Å. An example of a docking validation can be seen in Figure 2.

![Figure 2. Binding mode comparison between the docking pose of DHBT (green carbons) and the X-ray structure determined one (white carbons). Oxygen and nitrogen are shown in red and blue, respectively. The RMSD value is around 1 Å. For clarity, the surrounding protein has not been displayed.](image)

The docking results predicted that N-Me DHBT would indeed, be a HSV1 TK substrate since N-Me DHBT shows the same interactions known to thymidine and
DHBT. Specifically, the OH groups of N-Me DHBT and N-Me FHBT point towards the catalytic center of the enzyme, formed by E83 and R163. Due to these interactions, it was predicted that N-Me DHBT and N-Me FHBT would undergo phosphorylation since their hydroxyl functionalities mimic the 5’-hydroxyl group of thymidine. The second OH group of N-Me DHBT and the F atom of N-Me FHBT point towards the LID domain (residues 219-226) of HSV1 TK (Figure 3). Based on these results, both compounds fulfill the prerequisite for being HSV1 TK substrates.

![Figure 3. Binding modes of DHBT (left) and N-Me FHBT (right)](image)

**Synthesis of N-Me FHBT**

The synthesis of the key intermediate N-Me DHBT (Scheme 1) was accomplished in analogy to published procedures with slight modifications in the work-up [8, 9]. The starting compound, 2,4-dihydroxy-5,6-dimethylpyrimidine (1), was converted to the corresponding chloride 2 which was used without further purification. Treatment of 2 with sodium methanolate gave dimethoxy compound 3 in 95% yield after purification by column chromatography. In parallel, 1,3-dibenzyloxy-2-propanol (5) was oxidized using Corey oxidation to yield ketone 6. The product of the reaction between lithiated compound 4 and ketone 6 was the C-6 substituted pyrimidine 7. Removal of the tertiary hydroxyl group was accomplished using radical deoxygenation via oxalyl ester 8. Introduction of the methyl group in the N-1 position
of pyrimidine ring was achieved by the reaction of 9 with methyl iodide. Cleavage of two benzyl protecting groups, followed by the removal of the methoxy group gave N-Me DHBT in 13\% overall yield.

Scheme 1. Synthetic pathway to novel lead compound N-Me DHBT. Reagents and conditions: (i) POCl₃, reflux; (ii) NaOCH₃, MeOH; (iii) LDA, THF; (iv) N-Chlorosuccinimide, Et₃N, Toluene; (v) -55°C, THF; (vi) C₃H₅ClO₃, DMAP, CH₃CN; (vii) Bu₃SnH, AIBN, Toluene; (viii) CH₃I; (ix) -78°C, BCl₃, CH₂Cl₂; (x) Ac₂Cl, H₂O; NH₃, MeOH.
N-Me FHBHT was prepared in a three-step reaction sequence (Scheme 2) starting from the key intermediate N-Me DHBT (12). In the first step, one of the two hydroxyl groups was selectively protected with MTr (4-Methoxytrityl) protecting group. Fluorination was performed using DAST to give compound 14. The removal of MTr group was accomplished using 5% HCl in methanol. Pure reference compound, N-Me FHBT, was obtained in an overall yield of 2.8%. The structures of all compounds were confirmed with mass spectroscopy, $^1$H NMR, $^{13}$C NMR or $^{19}$F NMR spectroscopy.

The stability of N-Me FHBT in aqueous solution at room temperature was assessed over a period of 12 months during which no decomposition was observed.

**In vitro validation of N-Me DHBT**

In analogy to the previously published protocol [10], we initially investigated whether N-Me DHBT would be phosphorylated by HSV1 TK. Prior to assessing the phosphorylation of N-Me DHBT, we additionally validated the protocol using thymidine and DHBT as positive controls. As shown in Figure 4, thymidine (dT) and DHBT were readily phosphorylated by HSV1 TK. Formation of ADP and monophosphorylated substrate, as well as disappearance of the substrate over time are clearly visible. The retention times of N-Me DHBT and ADP are differed only by 0.2 minutes, making a clear distinction between the two components difficult. However, by magnifying a part of DAD (Diode Array Detector) chromatogram corresponding to the region with the retention times of N-Me DHBT and ADP (Figures 4 and 5), it was clearly seen that N-Me DHBT and ADP peaks overlap (Figure 5). As can be seen from Figure 4 (B), the absorption patterns at the beginning and at the end of the
overlapping peak belong to two distinct chemically different compounds. The maxima at 267 nm and 258 nm correspond to ADP and N-Me DHBT, respectively. The incubation of N-Me DHBT with HSV1 TK, also revealed the presence of a new peak at 7.05 minutes which corresponds to the monophosphorylated N-Me DHBT (Figure 4). An increase over time of this newly formed peak provided another evidence that N-Me DHBT is indeed a substrate of HSV1 TK.

All reactions were done in triplicates and the spontaneous hydrolysis of ATP was taken into consideration.

![Figure 4](image)

**Figure 4.** Phosphorylation pattern assay. The formation of new peaks (ADP and monophosphorylated product) has been monitored by HPLC coupled with diode array detector. To assess the functionality of the HSV1 TK enzyme, thymidine (dT) and DHBT were used as positive controls. These chromatogram clearly show the formation of ADP and monophosphorylated products dTMP and DHBT-P, respectively. For N-Me DHBT, the formation of N-Me DHBT monophosphate (N-Me DHBT-P) is clearly visible, while the peaks of N-Me DHBT and ADP overlap.

![Figure 5](image)

**Figure 5.** Presence of N-Me DHBT and ADP was confirmed by examining absorption patterns (B) at the beginning and at the end of the overlapping peak (A).
Quantitative enzyme kinetics measurements to determine $K_m$ and $K_{cat}$ were performed by spectrophotometric assay using a previously published protocol [11]. The experiments, performed in triplicate, showed that N-Methyl DHBT was phosphorylated at a similar rate to FHBG ($K_m=10\pm 0.3\mu M$, $K_{cat}=0.036\pm 0.015$ sec$^{-1}$). Compared to DHBT ($K_i=35.3 \pm 1.3\mu M$; $K_{cat}=0.035 \pm 0.01$ sec$^{-1}$), N-Me DHBT exhibits a similar affinity value suggesting that the introduction of a methyl group at the N-1 position of the pyrimidine ring of DHBT has no dramatic influence on the binding affinity of N-Me DHBT.

Cytotoxicity measurements were performed on B16F1 cells using XTT proliferation assay protocol [10,12]. No cytotoxic effect was observed using B16F1 TK+ and B16F1 wt cells even at concentrations where ganciclovir shows high cytotoxicity (Figure 7).

![Figure 7. Cytotoxicity comparison of ganciclovir (A) and N-Me DHBT (B) using B16F1 TK+ and B16F1 wt cells](image)
Radiolabeling of $[^{18}\text{F}] $N-Me FHBT

For the radiolabeling of $[^{18}\text{F}]$N-Me FHBT it was important to prepare a suitable precursor with a good leaving group. We decided for a tosyl leaving group since this precursor is potentially more lipophilic and can be well separated from the fluorinated product by HPLC. The tosylate precursor 15 was prepared by treating compound 13 with tosyl chloride in 30 % yield. Radiolabeling was carried out under classical conditions using potassium fluoride and kryptofix 2.2.2 in acetonitrile at 90°C (Scheme 3). Purification of the F-18 labeled intermediate 16 was achieved by passing the reaction mixture through a SepPak silica cartridge. The MTr protecting group was easily removed by 5% HCl in methanol during 10 minutes at reflux. Product was obtained by passing reaction mixture first through SepPak C-18 cartridge followed by purification on semi-preparative HPLC. Radiochemically pure $[^{18}\text{F}]$N-Me FHBT (>99 %) was obtained in 25 % RCY (decay corrected) after HPLC purification (Figure 9). In Figures 8 and 9 are shown the HPLC chromatograms of the reaction mixture before and after hydrolysis, respectively. Co-injection with the reference compound confirmed the identity of $[^{18}\text{F}]$N-Me FHBT.

Scheme 3: Synthesis of $[^{18}\text{F}]$N-Me FHBT
3. Development of a Novel C-6 Substituted Pyrimidine Derivative for Gene Therapy Monitoring

**Figure 8.** UV and radio HPLC chromatograms before hydrolysis

**Figure 9.** UV and radio HPLC chromatograms after hydrolysis
3. Conclusions

Molecular modeling was successfully employed to select a novel C-6 substituted pyrimidine derivative for development as a PET ligand for gene expression monitoring. The introduction of a methyl group at the N-1 position of the pyrimidine ring, did not have any dramatic effect on the binding properties of the methylated derivative. N-1 methylation of DHBT effectively prevented intramolecular cyclization and undesired side reactions. Novel lead compound, N-Me DHBT was shown to be a non-cytotoxic substrate for HSV1 TK. The radiosynthesis of [18F]N-Me FHBT was accomplished in good radiochemical yield.

In vitro validation including cell uptake studies, as well as in vivo PET studies are necessary to fully assess the biological properties of [18F]N-Me FHBT for monitoring HSV1 TK expression in vivo.

The fluorinated derivative is expected to have similar biochemical properties towards HSV-1 TK as N-methyl DHBT.

4. Materials and Methods

The 1H-NMR, 13C-NMR and 19F-NMR spectra were recorded on a 300 MHz Varian Gemini 2000 or a Bruker 400 MHz spectrometer with tetramethylsilane as an internal standard. Chemical shifts (δ) are reported in parts per million, and signals are expressed as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) or br (broad). The samples were dissolved in DMSO-d6, D2O or CD3OD and measured in 5mm NMR tubes. The 1H, 13C and 19F NMR chemical shift values (δ) are expressed in ppm referred to TMS and coupling constants (J) in Hz.

Mass spectroscopy analysis was performed with a Micromass Quattro micro TM API LC-ESI or a LCT Premier ESI-TOF from Waters.

TLC was done on Merck silica gel 60 F254 precoated plates. Compound was visualized under UV light (254 nm).

Silica gel used for column chromatography was Silica gel 60, particle size 0.040-0.063 mm (230-400 mesh ASTM), Fluka, Germany.
Evaporations were performed using Büchi Rotavapor R-215 system at 40°C.
Production of $[^{18}\text{F}]$ fluoride: No-carrier-added aqueous $[^{18}\text{F}]$fluoride ion was produced on an IBA Cyclone 18/9 cyclotron by irradiation of 2.0 ml water target (for a large volume target) or 0.585 ml (for a small volume target), using a 18 MeV proton beam on 98% enriched $[^{18}\text{O}]$water using the $[^{18}\text{O}(p,n)^{18}\text{F}]$ nuclear reaction.

HPLC 1 (analytical): Hitachi LaChrom Elite system equipped with UV diode array detector (DAD) and a column oven; column: analytical Merck LiChrospher C18 RP-18E, pore size: 100Å, particle size: 5 μm; flow rate: 1ml/min; temperature: 37°C; UV detection 220-400 nm.

HPLC 2 (analytical): Merck-Hitachi L6200A system equipped with UV multi-wavelength detector; column: analytical Merck LiChrospher RP-18E, pore size: 100Å, particle size: 5 μm; flow rate: 1ml/min; temperature: rt; UV detection at 254 nm or 275 nm.

HPLC 3 (analytical – radiolabeled compounds): Equipment: Agilent 1100 system equipped with a UV multi-wavelength detector; the radioactivity was monitored with a Raytest Gabi Star detector using a Gina software; column: analytical Merck LiChrospher RP-18E, pore size: 100Å, particle size: 5 μm; flow rate: 1ml/min; temperature: rt; UV detection at 254 nm.

HPLC 4 (semiprep): Merck-Hitachi system equipped with L6200A pump, Knauer variable wavelength detector and Eberline radiation monitor; column: semi-preparative Phenomenex Gemini C18, Pore size: 110Å, particle size: 5 μm; flow rate: 5ml/min; temperature: rt; UV detection at 254 or 275 nm.

**Docking studies using GOLD**
The hTK1 (PDB-ID: 1W4R) and HSV1-TK (PDB-ID: 1VTK) X-ray structures were retrieved from the PDB in pdb format. For each structure, monomer A was kept and hydrogens and Gasteiger charges added using Sybyl 7.2. Then, both structures were stored in mol2 format. For the putative ligands of hTK1 and HSV1-TK, hydrogens and Gasteiger-Huckel partial charges were assigned. Subsequently, the energy of each ligand was minimized using the Powell method with an initial Simplex optimization. The termination criterion was set to a gradient of 0.05 kcal/mol*A and the number of maximal iterations was 1000.

Standard Gold parameters (stored in gold.conf) were applied, except for the definition of the active site, where an origin was defined as center of a sphere with 6.5 A radius.
For hTK, its coordinates were 37.6736, 93.5756 and -19.4822 for x, y and z respectively. This corresponds to the centroid (centre of mass) of dTTP in subunit A of 1W4R. For HSV1-TK, these coordinates were set to 39.502, 16.7312 and 31.9443 (reflecting the centroid of dTMP in subunit A of 1VTk). For each compound, 10 gold runs were done.

**2,4-Dichloro-5,6-dimethylpyrimidine (2)**

A mixture of 2,4-dihydroxy-5,6-dimethylpyrimidine 1 (6.33 g, 45 mmol) and POCl₃ (30 ml, 328 mmol) was heated under reflux for 4 h. Excess of POCl₃ was then removed under reduced pressure and the residue was added to ice, washed with ether and dried over sodium sulphate. The crude product was recrystallized from ethanol to give 2 (7.54 g, 94.3 %, mp 70-71 °C); (C₆H₆N₂Cl₂), Rₚ = 0.65 (n-hexane/EtOAc = 5/1).

1H NMR (DMSO-d₆): 2.26 (s, 3H, CH₃); 2.47 (s, 3H, CH₃).

13C NMR (DMSO-d₆): δ 155.24 (C-2), 171.48 (C-4), 127.74 (C-5), 160.54 (C-6), 22.83 (CH₃), 14.40 (CH₃).

**2,4-Dimethoxy-5,6-dimethylpyrimidine (3)**

To a solution of sodium (2 g, 87.0 mol) in methanol (50 ml) was added 2 (7.54 g, 42.6 mmol). The reaction mixture was refluxed for 6 h. The solvent was evaporated and water was added to dissolve NaCl. The oily layer was extracted with dichloromethane, dried over sodium sulphate and concentrated under reduced pressure. The residue was kept in refrigerator and gave colorless crystals of 3 (7.10 g, 99.1 %, mp 39-40 °C).

1H NMR (DMSO-d₆): 1.98 (s, 3H, CH₃); 2.29 (s, 3H, CH₃); 3.82 (s, 3H, OCH₃); 3.87 (s, 3H, CH₃).

13C NMR (DMSO-d₆): δ 162.10 (C-2), 168.67 (C-4), 107.25 (C-5), 165.67 (C-6), 53.96 (OCH₃), 53.74 (OCH₃), 21.46 (CH₃), 9.67 (CH₃).
1,3-bis(benzyloxy)propan-2-one (6)
N-Chlorosuccinimide (18.0 g, 134.8 mmol) was suspended in dry toluene (210 ml), and the mixture was cooled in dry ice bath. Dimethyl sulfide (15 ml, 204.2 mmol) was added, and the mixture was cooled to -25°C in a dry ice-CH₂Cl₂ bath. 1,3-bis(benzyloxy)-2-propanol 5 (25.0 g, 91.8 mmol) in toluene (21 ml) was added to the mixture, and the mixture was kept under argon for 4 h. Triethylamine (100 ml, 717.5 mol) was added, and the reaction was allowed to warm to room temperature. After 30 min of stirring at room temperature, the solution was passed through a filter paper. The residue was washed with diethyl ether (250 ml). The filtrate and the washings were combined, neutralized with 5% aqueous HCl to pH 7, washed with saturated NaCl solution (3 x 50 ml) and then with water (3 x 50 ml), and finally dried over sodium sulphate. The solvent was removed in vacuum, and the resulting oil was purified by column chromatography (n-hexane/EtOAc = 4/1) to give 13.5 g (54.4 % yield) of compound 6 (C₁₇H₁₈O₃). mp 40 °C.

MS m/z: 270.1 (M⁺).

¹H NMR (DMSO-d₆): 7.23 (10H, Ph); 4.46 (s, 4H, CH₂Ph); 4.13 (s, 4H, CH₂O).

6-[[2-[1,3-bis(benzyloxy)-2-hydroxypropyl]methyl]-2,4-dimethoxy-5-methylpyrimidine (7)
LDA (1.5 M, 45 ml, 113 mmol) was added dropwise to a solution of 2,4 dimethoxy-5,6-dimethylpyrimidine 3 (7.50 g, 44.6 mmol) in THF (90 ml) at -70°C. The temperature was raised to -55°C, and the solution was stirred for 30 min. 6 (12.00 g, 44.4 mmol) in THF (65 ml) was added dropwise to this solution, and stirring was continued for 2.5 h while the temperature was maintained at -55°C. The solution was neutralized by the addition of AcOH to pH 7 and then the temperature was raised to 25°C, and the solvent removed. The residue was partitioned between AcOEt and H₂O. The organic layer was separated, dried over sodium sulfate and removed by evaporation. The residue was chromatographed on silica gel column, eluting with n-hexane/EtOAc = 3/1. The desired fractions were concentrated in vacuum to afford compound 7 in 59% yield (1.25 g).

MS m/z: 439.3 (M⁺).

¹H NMR (DMSO-d₆): 7.28 (10H, Ph); 5.09 (s, 1H, OH); 4.48 (s, 4H, CH₂Ph); 3.87 (s, 2H, CH₃); 3.76 (s, 3H, OCH₃); 3.44 (s, 3H, OCH₃); 2.83 (s, 2H, CH₂); 1.99 (s, 3H, CH₃).
6-(3-Benzyl-L-2- benzoxymethyl-propyl) 2,4-dimethoxy-5-methyl pyrimidine (9)
Methyl oxalyl chloride (5.9 ml, 63.7 mmol) was added to a mixture of 6-[2-[1,3- bis(benzyloxy)-2-hydroxypropyl][methyl]-2,4-dimethoxy-5-methyl-pyrimidine (6.00 g, 13.7 mmol) and 4-(dimethylamino) pyridine (DMAP, 3.7 g, 29.6 mmol) in dry CH₃CN (50 ml) at 0°C under argon. The mixture was stirred for 14h under argon at room temperature and then diluted with EtOAc (400 ml). The mixture was washed successively with saturated aqueous NaHCO₃ solution (120 ml) and H₂O (120 ml). The separated organic phase was dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was coevaporated twice with dried toluene (40 ml) to afford the methyl oxalyl ester 8. MS m/z: 481 (M+).
A mixture of Bu₃SnH (9.0 ml, 36 mmol) and 2,2′-azo bis (isobutyronitrile) (AIBN; 180 mg, 1.1 mmol) in dry toluene (50 ml) was added to a solution of 8 in dry toluene (130 ml) under an argon atmosphere. The mixture was heated at 110°C for 3h and the solvent was removed by evaporation under reduced pressure. The residue was purified by column chromatography (mixture of n-hexane/EtOAc = 4/1 as mobile phase) to afford 2.77 g of 6-[3-benzyloxy-2-[(benzyloxy)methyl] propyl] thymine 9 in 48% yield.
MS m/z: 423.3 (M+).
¹H NMR (DMSO-d₆): 7.29 (10H, Ph); 4.42 (s, 4H, CH₂Ph); 3.87 (s, 3H, OCH₃); 3.79 (s, 3H, OCH₃); 3.43 (d, 4H, OCH₂); 2.68 (d, 2H, CH₂); 1.97 (s, 3H, CH₃).

6-(3-(benzyloxy)-2-(benzyloxymethyl)propyl)-4-methoxy-1,5-dimethylpyrimidin-2(1H)-one (10)
Mixture of 9 (3.6 g, 7.57 mol) and CH₃I (50 ml, 803 mol) was refluxed at 50°C for 4 days and evaporated to dryness. Raw product was purified on silica column (n-pentane/EtOAc = 1/1) to afford 3.5 g of pure 10 in 97% yield.
MS: 423.3 (M⁺)
¹H NMR (CDCl₃): 7.24 (m, 10H, Ph); 4.40 (q, 4H, CH₂); 3.88 (s, 3H, CH₃); 3.45 (s, 3H, CH₃); 3.42 (d, 4H, CH₂); 2.78 (d, 2H, CH₂); 2.10 (m, 1H, CH); 2.95 (s, 3H, CH₃).
6-(3-hydroxy-2-(hydroxymethyl)propyl)-4-methoxy-1,5-dimethylpyrimidin-2(1H)-one (11)
A mixture of 10 (3.2 g, 7.57 mmol) in dry CH₂Cl₂ (40 ml) was cooled to -78°C. BCl₃ (1M in CH₂Cl₂, 35 ml, 35 mol) was added via syringe and under argon. The mixture was stirred at -78°C for 2h, and then the temperature was raised to -40°C. A mixture of CH₂Cl₂/MeOH (1/1; 100 ml) was added, and the cooling bath was removed. The solution was neutralized with saturated NaHCO₃ solution to pH 7 and stirred for additional 30 min. The water layer was separated and solvent was removed under reduced pressure to give 1.65 g of pure 11 in 90% yield.
MS m/z: 243.3 (M⁺).
¹H NMR (CDCl₃): 1.96 (s, 3H, CH₃); 2.01 (br, 1H, CH), 2.83 (m, 2H, CH₂); 3.47 (s, 3H, CH₃); 3.58 (m, 4H, CH₂ + CH₂); 3.87 (s, 3H, OCH₃).

6-(3-hydroxy-2-(hydroxymethyl)propyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione (N-Me DHBT) (12)
A solution of 11 (3.0 g, 12.4 mmol) dissolved in acetyl chloride (10 ml) and containing a few drops of water was stirred at reflux for 48 hrs. The solvent was removed under reduced pressure and the residue was dissolved in saturated methanolic ammonia (50 ml), stirred at rt for additional 4 h, and then evaporated to dryness. The product was purified on a silica column (CHCl₃/i-PrOH=4/1) to give pure N-Me DHBT (1.3 g) in 46% yield.
MS m/z: 229.17 (M⁺).
¹H NMR (CDCl₃): 1.86 (s, 3H, CH₃); 1.96 (m, 1H, CH); 2.73 (d, 2H, CH₂); 3.35 (s, 3H, CH₃); 3.58 (m, 4H, CH₂ + CH₂).
¹³C NMR (CDCl₃): 10.96 (CH₃); 28.08 (C₁’); 31.80 (N-CH₃); 41.65 (C₂’); 61.15 (C₃’,C₄’); 109.44 (C₅); 153.85 (C₂, C₄).

6-(3-hydroxy-2-(((4-methoxyphenyl)diphenylmethoxy)methyl)propyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione (13)
Solution of 12 (100 mg, 0.44 mmol) in dry pyridine (25 ml) under argon, was cooled down to 0°C. 4-Di(methylamino)pyridine (DMAP, 135 mg, 1.1 mmol) was added to the reaction, and obtained mixture was stirred at 0°C for 15 min. 4-Methoxytriphenylmethyl chloride (150 mg, 0.48 mol) was added, reaction is warmed up to 50°C and stirred for 3 hrs. Reaction mixture was partitioned between
3. Development of a Novel C-6 Substituted Pyrimidine Derivative for Gene Therapy Monitoring

CH$_2$Cl$_2$ (250 ml) and saturated aqueous solution of CuSO$_4$ (250 ml). Aqueous layer was washed 3 times with CH$_2$Cl$_2$ (100 ml). All organic layers were combined and evaporated to dryness. Pure 13 was obtained after purification on a silica column (CHCl$_3$/i-PrOH=9/1) in 20% yield.

MS m/z: 501.3 (M$^+$).

$^1$H NMR (CDCl$_3$): 1.75 (s, 3H, CH$_3$); 1.93 (m, 1H, CH); 2.57 (m, 2H, CH$_2$); 3.20 (m, 2H, CH$_2$); 3.28 (s, 3H, N-CH$_3$); 3.60 (m, 2H, CH$_2$); 3.71 (s, 3H, OCH$_3$); 6.73-7.34 (m, 14H, Ph).

6-(3-fluoro-2-(((4-methoxyphenyl)diphenylmethoxy)methyl)propyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione (14)

Solution of 13 (37 mg, 73.9 μmol) in dry CH$_2$Cl$_2$ (15 ml) under argon, was cooled down to -78°C and stirred for 10 min. (Dimethylamino)sulfur trifluoride (50 μl, 378 μmol) was added dropwise and reaction was kept at -78°C for additional 10 min and cooling was removed. After 45 min of stirring at room temperature, saturated aqueous solution of NaHCO$_3$ was added (10 ml) and reaction was partitioned. Organic layer was separated and evaporated to afford 33 mg of raw 14 (89% yield).

MS m/z: 503.3 (M$^+$).

6-(3-fluoro-2-(hydroxymethyl)propyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione (N-Me FHBT)

Solution of raw 14 (33 mg) was dissolved in 5% HCl in CH$_3$OH was refluxed 15 min at 90°C under argon after which the solvent was removed. Pure N-Me FHBT (2.1 mg) was obtained after HPLC purification in 12% yield.

$^{19}$F NMR (DMSO-d$_6$): -224 (m).

3-(3,5-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-2-(((4-methoxy phenyl)diphenylmethoxy)methyl)propyl 4-methylbenzenesulfonate (15)

Solution of 13 (44 mg, 87.9 μmol), triethylamine (30μl, 215 μmol) and trimethylamine hydrochloride (1 mg, 10 μmol) in dry CH$_2$Cl$_2$ under argon was cooled down to 0°C. Tosyl chloride (20 mg, 104.9 μmol) was added and reaction mixture was stirred at 0°C for 2 hrs and solvent was removed. After HPLC purification, 17.3 mg of pure 15 were obtained (30% yield).

MS m/z: 655.4 (M$^+$).
6-(3-[18F] fluoro-2-(hydroxymethyl)propyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione ([18F] N-Me FHBT)

To a 10-mL Pyrex brand tube with screw cap containing 10 mg Kryptofix 2.2.2 and 2 mg of K₂CO₃ was added 20 GBq ¹⁸F-fluoride. Water was azeotropically evaporated from the mixture using dry CH₃CN (3 x 0.9 mL) at 90°C under a stream of nitrogen. After the final drying sequence, 2 mg of 15 dissolved in 300 μl dry CH₃CN were added to the F-18 residue. Reaction was carried out at 90°C for 30 min. Mixture was passed through Sep Pak Silica cartridge and washed with 3.5 ml of CH₃CN and solvent is evaporated at 90°C under the stream of nitrogen. 300 μl of HCl (5% in CH₃OH) was added and reaction was kept for 10 min at 90°C after which it was allowed to cool down to room temperature. Water (4.7 ml) was added and the mixture was purified on HPLC. 2.4 GBq of pure [¹⁸F]N-Me FHBT in 2.0 ml was collected after 23 min (25 % RCY after decay correction).

HPLC assay for monitoring the phosphorylation of N-Me DHBT

Reactions were carried out in a final volume of 75 μl containing H₂O (58.2 μl), 1M Tris buffer, pH 7.4 (3.75 μl), 100 mM ATP (3.75 μl), 100 mM MgCl₂ (3.75 μl), 1mM N-Me DHBT (3.75 μl) and 2-10 μg of the HSV1 TK. The reaction were carried at 37°C and were stopped by addition of 2.5 mM EDTA (675 μl) at time-points: 10, 20, 30, 45, 60 and 90. Obtained mixture was then injected into HPLC for the analysis. The formation of the monophosphorilated compound, as well as, ADP was monitored qualitatively. Two different blank reactions (no enzyme or no substrate) were run concurrently to account for the occurring minimal reaction independent ATP hydrolysis. All reactions were performed in triplicates. HPLC System: HPLC 1, using a previously published protocol [13]. (Column, C-18; solvent, 0.2 M NaH₂PO₄, 25 mM tetrabutylammonium hydrogen sulphate, 3% methanol; flow 1.1 ml/min; detection, diode array detector).

Determination of kcat by spectrophotometric assays

The Kcat values were determined as described in the literature [11]. Reaction mixture with a final volume of 75 μl containing 50 mM Tris buffer pH 7.2, 1 mM 1,4-dithio-DL-threitol, 0.21 mM phosphoenolpyruvate, 2.5 mM MgCl₂, 5 mM ATP, 0.18 mM NaDH, 0.8 μg pyruvate kinase, 0.5 μg L-lactate dehydrogenase, and different concentrations of the substrate (0.01 mM, 0.05 mM, 0.1 mM, 0.25 mM, 0.5 mM, 1
mM) were incubated at 37°C. Two minutes later, 5 μg of HSV1 TK was added in order to initiate the reaction. The changes in absorbance at 340 nm corresponding to ADP formation of the TK-dependent reaction at 37°C were monitored during 20 minutes. The data presented are the results of the measurements performed in triplicate. Control experiments were performed in order to take into account the spontaneous hydrolysis of ATP under the experimental conditions.

**Cell proliferation assay**

Confluent B16F1 TK+ (HSV-1 TK transduced cells) and wt cells were trypsinised and ingested in 10 ml of fresh RPMI 1640 medium with 10% foetal calf serum and 1% antibiotic PSF solution. The cell concentration of a 1:1 dilution with trypan blue was determined using a Neubauer’s counting chamber. The suspension was diluted with medium to a final concentration of 20000 cells per ml.

100 μl of the suspension (2000 cells) were seeded in each well of a 96 well NunclonTM Surface plate from NuncTM. After 1.5 h incubation at 37°C, the cells were attached to the bottom of the wells. 100 μl of sterile solutions of GCV and N-Me DHBT in RPMI 1640 were added to the cells leading to final substrate concentrations of 0.05, 0.1, 1, 5, 10, 50, 100, 500, and 1000 μM. All samples were prepared in triplicate for each cell line. The wells with no thymidine analogue allow calculating the standard value of 100% of cell growth. The plates were incubated for 3.5 days at 37°C in presence of 5% CO2. Viability of the cells was measured using XTT reagent. 50 μl of the XTT reagent were added to each well. While the plates were incubated at 37°C in presence of 5% CO2, the living cells converted the XTT (tetrazolin derivative) by biodegradation to a water-soluble reddish formazan derivative [10, 12]. After 9 h incubation the number of viable cells in each vial was determined by colorimetric UV absorption measurement of the converted XTT with an ELISA reader at a wavelength of 450 nm. To account for absorbance due to the presence of varying numbers of cells and non-metabolized XXT, the optical density (OD) at a reference wavelength of 750nm was subtracted [10,12].
5. References


4 Overall Conclusions & Outlook
4. Overall conclusions and outlook

An optimized synthesis of the key intermediate DHBT was a necessary prerequisite for the development of FHBT. The 10-step synthesis of DHBT was successfully optimized and the overall yield was increased 10-fold. Using numerous synthetic approaches from different starting compounds, the preparation of target compound FHBT was unsuccessful. Although we successfully produced F-19 and F-18 fluoro derivatives of DHBT in the presence of MTr protecting group, neither FHBT nor \([^{18}\text{F}]\text{FHBT}\) were isolated.

As suggested in Chapter 2, one novel possibility to prepare FHBT would be by introduction of the fluorine atom at the very beginning of the synthesis (Scheme 2.21). Additionally, it should be possible to use chlorine instead of fluorine, since chlorine could be substituted with \(^{18}\text{F}\) (see page 54).

N-1 methylated DHBT (N-Me DHBT) was successfully synthesized in 10-step reaction sequence. Enzyme kinetics confirmed that N-Me DHBT is indeed a substrate for HSV1 TK. Methylation on N-1 position effectively prevented intramolecular cyclization and undesired side reactions, thus making the synthesis of cold reference and radiolabeling with F-18 possible. Further in vitro validation (cell uptake studies) as well as in vivo studies are necessary to fully assess the biological properties of \([^{18}\text{F}]\text{N-Me FHBT}\) for the monitoring of HSV1 TK expression in vivo.

A pool of new compounds is necessary to fully assess the binding affinity of C-5 and C-6 substituted N-1 methylated class of compounds. A novel method for preparing C-5 and C-6 substituted pyrimidine derivatives from acetoacetate derivatives and urea is shown in Scheme 4.2.

\[ \text{Scheme 4.2 A microwave approach to C-5 and C-6 pyrimidine derivatives from acetoacetate esters and urea} \]

One example which could be tried in future synthesis, starts from commercially available ester \(\text{M1}\). \(\text{M1}\) would then react with urea (\(\text{M2}\)) to produce C-5 and C-6 substituted derivative \(\text{M3}\). Methylation at the N-1 position followed by removal of the methoxy group would give key intermediate \(\text{M4}\) (Scheme 4.3).
Free hydroxyl group of $\text{M4}$ provides excellent opportunities to prepare a series of compounds using relatively simple and straightforward synthetic procedures.

Compounds which would be substrates for viral TK could easily be converted into corresponding fluorinated analogues by using already fluorinated $\text{M5}$ derivative (Scheme 4.4). Additionally, it would be possible to prepare F-18 labeled $\text{M5}$ analogues and use them for the synthesis of radiolabeled compounds for gene therapy monitoring and screen their potential as a HSV1 TK substrates.
Curriculum Vitae

Miljen Martić

Address: Breitensteinstr. 94
CH-8037 Zurich, Switzerland
E-mail: miljen.martic@pharma.ethz.ch

Education / Qualifications

2004 – present ETH Zurich, Institute of Pharmaceutical Sciences, Switzerland
PhD in Radiopharmaceutical Sciences
• Title: Development of new nucleoside analogues as PET imaging agents for monitoring gene expression
• Supervisors: Prof. P. A. Schubiger and Prof. S. M. Ametamey

2005 Paul Scherrer Institute, Villigen, Switzerland
Radiation Safety Officer for B- and C-laboratories

1997 – 2002 University of Zagreb, Faculty of Science, Croatia
Diploma in chemistry (organic chemistry major)
• Title: Synthesis and molecular modeling of 1,1-di-(3-carboxyphenyl)ethane derivatives
• Supervisors: Prof. Dr. V. Šunjić and Dr. N. Kujundžić

2002 Algebra, Zagreb, Croatia
Internet Application Programmer
International license for programming internet applications using Active Server Pages (ASP), VBScript, JavaScript and integration with MS Access

Languages

<table>
<thead>
<tr>
<th>Language</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Croatian</td>
<td>Mother tongue</td>
</tr>
<tr>
<td>English</td>
<td>Fluent, both spoken and written – Senior year of high school spent as an exchange student in West Chester, PA, USA</td>
</tr>
<tr>
<td>German</td>
<td>Intermediate conversational level (B1)</td>
</tr>
</tbody>
</table>

Publications

• M. Martić et al., Development of new F-18 labeled C-6 pyrimidine derivative for gene expression monitoring, manuscript in preparation
Oral and Poster Presentations

**Oral**
- 17th International Symposium on Radiopharmaceutical Sciences (ISRS), May 2007, Aachen, Germany
- SGR/SGNM, June 2006, Lausanne, Switzerland
- 13. Arbeitstreffen der Arbeitsgemeinschaft Radiochemie / Radiopharmazie, October 2005, Seefeld, Austria
- Doktorandentag, March 2006, ETH Zurich, Switzerland

**Poster**
- ZNZ Symposium, October 2005, Zurich, Switzerland

Honors & Awards

- U.S. National Chemistry Olympiad, top 15% in Pennsylvania, USA, 1997
- American Chemical Society award certificate for recognition of achievement in high school chemistry, 1997
- Travel grant for the attendance of the 17th International Symposium on Radiopharmaceutical Sciences (ISRS), May 2007, Aachen, Germany